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Overview of the thesis 
 
Age-related macular degeneration (AMD) is the leading cause of visual loss in people over 50 
years of age in developed countries. AMD is a degenerative disorder affecting the macula and is 
characterized by the presence of specific clinical findings. Conventionally AMD is divided into 
two main types, dry (non-exudative) AMD and wet (exudative/neovascular) AMD. Dry AMD is 
the most common form with geographic atrophy (GA) a sign of advanced stage of disease. 
Neovascular AMD is associated with more rapid progression to advanced sight loss but is less 
common. 
For neovascular AMD (nAMD) the standard of care at present are inhibitors of vascular 
endothelial growth factor (anti-VEGF), of which there are three currently on the market. 
Bevacizumab (trade name Avastin) is a recombinant humanized monoclonal antibody that 
blocks angiogenesis by inhibiting vascular endothelial growth factor-A, and is used off-label for 
nAMD. Ranibizumab (trade name Lucentis ) is a monoclonal antibody fragment (Fab) created 
from the same parent mouse antibody as bevacizumab and has U.S. Food and Drug 
Administration (FDA) approval for the treatment of neovascular AMD. Aflibercept (trade 
name Eylea) is a soluble decoy receptor that binds vascular endothelial growth factor-A and 
placental growth factor-And also has FDA approval for the treatment of nAMD. Not only do the 
anti-VEGF drugs maintain vision they also improve vision which was not possible before their 
introduction onto the market around 2007, which was a major step forward in the 
management of nAMD patients. 
Bevacizumab is by far much more cost effective option as it is marketed for certain metastatic 
cancers including metastatic colon cancer which was approved by the FDA in 2004. Using only 
one vial, one can treat at least twenty patients with nAMD. The intravitreal injection is 
prepared in compounding pharmacies from the vial of bevacizumab. Bevacizumab has been 
proven to be as effective and safe as Ranibizumab in major prospective randomized clinical 
trials and in the resource limited public health sector bevacizumab is the drug of choice for 
nAMD. 
The purpose of the study was to determine if the clinical outcomes of patients using intravitreal 
bevacizumab with a treat-and-extend regimen (TER) for nAMD resulted in and maintained the 
same visual gains as a monthly regimen does as was determined in major prospective 
randomized clinical trials. The benefit of a TER is that it can drastically decrease the number of 
clinic visits and the number of injections received by patients. In a resource limited sector, such 
as the public health sector, this would drastically save costs and decrease the burden on the 
health practitioners as well as the whole public health system when managing these patients.  
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At present there are three treatment regimen options for nAMD using bevacizumab: Fixed 
monthly injection regimen (FMR), pro re nata (PRN) regime with monthly follow-up, and TER. 
FMR is the regimen adopted in the initial major landmark trials. Patients are seen every month 
and injected every month. This regimen has proven to give the best visual outcome and is seen 
as the gold standard. Many different dosing options have been tried in multiple clinical trials to 
attempt to decrease the burden on the health sector. Quarterly dosing, injecting every three 
months, and PRN with less than monthly follow-up were shown to be inferior to fixed monthly. 
PRN regime with monthly follow-up was shown to have results similar to fixed monthly but was 
still inferior and very importantly still requires patients to be seen monthly. TER is an alternative 
type of PRN regime that entails administering three initial injections at monthly intervals and 
then to continue monthly injections until the retina is dry as determined using optical 
coherence tomography (OCT). After the retina is dry the period between injections are 
gradually increased by 2 weeks at a time and continued injections at every visit regardless if 
retina is dry or not. If fluid accumulates again the period between injections is decreased by 2 
weeks at a time until a stable interval is determined for each individual patient. This regimen 
cuts down on clinic visits and the number of injections and maintains vision according to results 
from past and ongoing clinical trials.  
A retrospective chart review was undertaken of all patients with nAMD that presented to Inkosi 
Albert Luthuli Central Hospital (IALCH) since records were kept. 53 eyes of 48 patients met the 
entry criteria from June 2011 until June 2016. The main outcome measures were: mean change 
from baseline visual acuity at year 1 and 2, mean change from baseline central macular 
thickness at year 1 and 2, mean number of intravitreal bevacizumab injections at year 1 and 2 
and mean period of extension between intravitreal bevacizumab injections. 
In reviewing the charts it was ascertained that patient’s vision did indeed improve significantly 
from baseline at year 1 and 2. It was noticed during review of the charts that many patients did 
not follow an absolute and strict TER, either due to poor follow-up due to social circumstances, 
such as finance or transport issues, or clinician error when deciding on intravitreal injection 
frequency. This resulted in a mixture of TER and PRN regimen being followed in many patients, 
which could reveal a more real world experience. 
This study has shown that our current treatment for nAMD is resulting in significant visual gains 
but our implementation of the TER can be followed more strictly. Areas identified where 
intervention would make a difference include, education of treating Ophthalmologists, 
especially the junior registrar’s and medical officers, on the TER protocol, educating patient on 
the importance of follow-up on correct clinic appointments and possible down referring 
patients back to base ophthalmology clinics with the adequate staff and equipment for 
management and follow-up. This would be much more convenient for patients as IALCH 
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ophthalmology clinic is one of only two clinics in Kwa-Zulu-Natal currently providing this service 




Table of Contents 
 
 
Declaration ........................................................................................................................... ii 
Acknowledgements .............................................................................................................. iii 
Overview of the thesis .......................................................................................................... iv 
Table of Contents ................................................................................................................ vii 
List of Tables ........................................................................................................................ ix 
Part 1: The Review of Literature............................................................................................. X 
Introduction................................................................................................................................. X 
History of the treatment of nAMD ............................................................................................ XII 
Photocoagulation .................................................................................................................. XII 
Photodynamic therapy .......................................................................................................... XII 
Introduction of anti-vascular endothelial growth factor ...................................................... XII 
Fixed monthly regimen ......................................................................................................... XIII 
Less than monthly follow-up ................................................................................................ XIII 
Pro re nata (PRN) with monthly follow-up ........................................................................... XIV 
Fixed monthly versus Pro re nata with monthly follow-up. .................................................. XV 
Treatment regimen options for bevacizumab ........................................................................ XVII 
Treat-and-extend versus PRN dosing .................................................................................. XVII 
Treat-and-extend versus fixed monthly dosing................................................................... XVII 
What other benefits are there of fewer intravitreal injection of Anti-VEGF? ................... XVIII 
Conclusion ................................................................................................................................ XIX 
Key References .......................................................................................................................... XX 
Part 2: A submission ready manuscript. ............................................................................. XXII 
Cover Page ............................................................................................................................... XXII 
Summary ................................................................................................................................. XXII 
Introduction............................................................................................................................ XXIV 
Research methods and design ............................................................................................... XXVI 
viii 
 
Patient Selection ................................................................................................................. XXVI 
Statistical Analysis .............................................................................................................. XXVI 
Ethical considerations ........................................................................................................ XXVII 
Results .................................................................................................................................. XXVIII 
Discussion .............................................................................................................................. XXXII 
Fixed Monthly Regimen ..................................................................................................... XXXII 
Less than monthly follow-up ............................................................................................ XXXIII 
Pro re nata with monthly follow-up ................................................................................. XXXIII 
Fixed monthly versus Pro re nata with monthly follow-up .............................................. XXXIV 
Treat-and-Extend: IALCH ................................................................................................... XXXV 
Treat-and-extend versus pro re nata with monthly follow-up ......................................... XXXV 
Treat-and-extend versus fixed monthly regimen ............................................................. XXXVI 
What other benefits of fewer intravitreal injection of Anti-VEGF? ................................. XXXVI 
Limitations of the study .................................................................................................. XXXVIII 
Conclusion .................................................................................................................................. XL 
Fixed Monthly Dosing Studies .............................................................................................. XL 
Acknowledgements .................................................................................................................. XLII 
Authors' contributions ............................................................................................................. XLII 
References ............................................................................................................................... XLIII 
Appendix 1: The final Study Protocol ................................................................................. XLV 
Appendix 2: The Guidelines for Authorship for the submission Journal ............................. XLVI 
Appendix 3: Ethical approvals .......................................................................................... XLVII 






List of Tables 
 
Table 1: Age .............................................................................................................................. XXVIII 
Table 2: Sex .............................................................................................................................. XXVIII 
Table 3: Race ............................................................................................................................ XXVIII 
Table 4: Visual Acuity ................................................................................................................. XXIX 
Table 5: Central Retinal Thickness .............................................................................................. XXX 
Table 6: Number of Injections .................................................................................................... XXX 
Table 7: Number of Weeks between Injections ........................................................................ XXXI 
Table 8: Fixed Monthly Dosing Studies .......................................................................................... XL 
Table 9: PRN Dosing With Monthly Follow-up Studies ................................................................. XLI 
Table 10: TER Studies .................................................................................................................... XLI 
X 
 




Age-related macular degeneration (AMD) is the leading cause of visual loss in people over 50 
years of age in developed countries [1]. AMD is a degenerative disorder predominantly 
affecting the macula. [6] 
AMD is divided into two main types, dry (non-exudative) AMD and wet (exudative/neovascular) 
AMD. [2] Dry AMD is the most common form with geographic atrophy (GA) a sign of advanced 
stage of disease.  
Neovascuar AMD (nAMD) only found in 10% to 20% of patients with AMD but accounts for 90% 
of vision loss from AMD and is associated with more rapid progression to advanced vision 
loss.[7] The main manifestations of nAMD are choroidal neovascularization (CNV). CNV are new 
abnormal blood vessels that grow in the choroid and break through the barrier between the 
choroid and the retina into the sub-retinal pigment epithelium (type 1) or subretinal (type 2) 
space. [2] Terminology used to describe CNV on fundus fluorescein angiography (FFA) was 
derived from the Macular Photocoagulation Study. Classic CNV fills with dye in a well-defined 
‘lacy’ pattern during early transit of the dye. With Occult CNV the limits cannot be fully defined 
on FA. Predominantly or minimally classic CNV is defined as the classic element of the lesion on 
FFA is greater or less than 50% of the total lesion. [2] Untreated CNV forms scar tissue that 
eventually replaces normal retina tissue, causing irreversible visual loss.  
The aetiology of AMD is not fully understood. Genetic risk factors and environmental risk 
factors, such as smoking, may contribute to the development and progression of AMD. Smoking 
roughly doubles the risk of AMD[1] while genetic factors, such as complement factor H gene 
and complement component 3 genes, are consistent with an inflammatory basis for the 
development of AMD .[6] Age is another major risk factor. AMD is also more common in 
Caucasians than other races. Hypertension, high fat intake and obesity, cataract surgery, blue 
iris colour, high sunlight exposure, and female gender are suspected. [2] 
Treatment for dry AMD at intermediate or advanced stage is high dose of micronutrient 
supplementation as determined by the Age-related Eye Disease Study 1 ( AREDS 1) and Age-
related Eye Disease Study 2 (AREDS 2)[7] In AREDS 1 progression to advanced AMD occurred in 
28% of placebo group and 20% of micronutrient group, which included 500 mg vitamin C, 400 
IU vitamin E, and 15 mg β– carotene, 80 mg Zn and 2 mg copper.[ 8] In AREDS 2 because of the 
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increased risk of lung cancer in smokers who take β-carotene, β-carotene was substituted by 
lutein and zeaxanthin. The evidence from AREDS 2 on the beneficial and adverse effects of 
substituting lutein and zeaxanthin for B-carotene suggests it could be more appropriate than β- 
carotene in AREDS-type supplements. [9 ] It is therefore suggested that current and previous 
smokers use the AREDS formula substituting lutein and zeaxanthin for β-carotene. Current 
management of dry AMD include annual surveillance of patients above 60 years and cessation 
of smoking. No evidence supports supplements for early dry AMD but patients with 
intermediate or advanced dry AMD should self-monitor vision at home with an Amsler grid and 
should take AREDS supplements. Therapies that inhibit complement and alter visual cycle are 
being tested and for severe disease stem cell therapy is being tested.[7]  
When patients progress to advanced AMD with CNV under the fovea, they are classified as 
having nAMD. [1] For nAMD the standard of care at present are inhibitors of vascular 
endothelial growth factor (anti-VEGF), of which there are three currently on the market. 
Bevacizumab (trade name Avastin) is a recombinant humanized monoclonal antibody that 
blocks angiogenesis by inhibiting vascular endothelial growth factor-A, and is used off-label for 
nAMD. Ranibizumab (trade name Lucentis ) is a monoclonal antibody fragment (Fab) created 
from the same parent mouse antibody as bevacizumab and has U.S. Food and Drug 
Administration (FDA) approval for the treatment of nAMD. Aflibercept (trade name Eylea) is a 
soluble decoy receptor that binds vascular endothelial growth factor-A and placental growth 
factor, and also has FDA approval for the treatment of nAMD.  
Not only do the anti-VEGF drugs maintain vision they also improve vision which was not 
possible before their introduction onto the market around 2007, which was a major step 





History of the treatment of nAMD 
 
Photocoagulation 
The first effective treatment of CNV was thermal laser photocoagulation. In 1982 the Macular 
Photocoagulation Study Group reported that patients receiving argon laser treatment to 
extrafoveal and juxtafoveal CNV lesions had a decreased rate of visual decline compared to 
untreated control group. Note that because this treatment however caused irreversible 
damage to the overlying neurosensory retina it was not appropriate for subfoveal lesions. This 
treatment also had a recurrence rate of more than 50% [1]. 
Photodynamic therapy 
Photodynamic therapy (PDT) introduced in 2000 offered an alternative to thermal laser 
photocoagulation. PDT selectively targets CNV without damaging the overlying retinal tissue. 
Verteporfin, an intravenously injected photosensitizing dye, preferentially accumulates within 
the neovascular tissue. Non-thermal laser light of 689nm for 83 seconds activates the 
verteporfin which forms free radicals causing endothelial damage and thrombosis of the 
choroidal vessels. [1] The Therapy of Age-related macular degeneration with Photodynamic 
therapy (TAP) Study Group conducted a randomized trial comparing PDT with placebo and 
analysed visual acuity loss between the 2 groups. At 2 years of follow-up after randomization, 
53% of PDT patients lost 15 or fewer letters of visual acuity, compared to 38% of placebo 
patients which was statistically significant. PDT was however less effective in some CNV types 
and it was recommended that verteporfin therapy be used for the treatment of patients with 
subfoveal predominantly classic l CNV from nAMD. [11] 
By 2000 we had two options for the treatment of CNV in nAMD: Thermal laser 
photocoagulation for extrafoveal and juxtafoveal CNV lesions and PDT for subfoveal 
predominantly classic l CNV. PDT is less destructive method of treatment compared to laser but 
was not associated with any visual acuity gain.[1] We also did not have effective treatment for 
subfoveal minimally classic and occult CNV.   
Introduction of anti-vascular endothelial growth factor 
The development of pharmacologic agents that specifically target angiogenesis, such as anti-
VEGF drugs, has revolutionized the treatment of nAMD.[3] VEGF increases the growth of 
abnormal blood vessels and augments vascular permeability. VEGF is up-regulated by hypoxia, 




Pegaptanib sodium (trade name Macugen) was the first drug directed against VEGF. Pegaptanib 
is an aptamer that directly binds to VEGF165 and prevents it from activating DNA transcription. 
Pegaptanib is administered by intravitreal injection every six weeks. [1] The VEGF Inhibition 
Study In Ocular Neovascularization (VISION), studied patients with all angiographic choroidal 
neovascularization lesion compositions of nAMD and received either intravitreal pegaptanib 
sodium (0.3 mg, 1 mg, 3 mg) or sham injections every 6 weeks for 54 weeks. The results in the 
VISION trial showed that pegaptanib had a beneficial effect for all subtypes of 
neovascularisation. We now had an effective and safe treatment for subfoveal minimally classic 
and occult CNV as well .The majority of patients in the pegaptanib clinical trials still lost vision 
but at a slower rate, and the treatment is considered one that slows the disease rather than 
one that improves visual acuity.[10] Because newer more effective anti-VEGF soon followed, 
pegaptanib was no longer used for the treatment of CNV due to AMD. 
Fixed monthly regimen 
Ranibizumab (Lucentis) is a recombinant anti-VEGF monoclonal antibody fragment that is 
capable of inhibiting all active forms of VEGF in the eye. Two major studies have examined the 
effects of ranibizumab in eyes with nAMD. The phase III Minimally Classic/Occult Trial of the 
Anti-VEGF Antibody Ranibizumab in the Treatment of Neovascular Age-Related Macular 
Degeneration (MARINA) trial, and The Anti-VEGF Antibody for the Treatment of Predominantly 
Classic Choroidal Neovascularization in Age-Related Macular Degeneration (ANCHOR) trial. 
MARINA compared ranibizumab with sham injection for treatment of minimally classic and 
occult nAMD. ANCHOR compared ranibizumab with PDT in patients with classic CNV. MARINA 
and ANCHOR trials were both 2‑year, multicentre, double blind, randomized control trials, and 
demonstrated that visual acuity outcomes when treating nAMD with fixed monthly 
regimen(FMR) of intravitreal ranibizumab was far superior to any other treatment to date. [4]  
MARINA and ANCHOR trials demonstrated significant visual gain for the first time in the history 
of treatment of nAMD. Ranibizumab was licenced by the FDA in 2006 and in Europe in 2007.[6] 
Less than monthly follow-up 
Subsequent studies followed MARINA and ANCHOR which aimed at reducing frequency of 
injections. Monthly intravitreal injection is a major burden on patients and the health system. 
Alternative fewer fixed scheduled injections have not resulted in visual outcomes that were as 
favourable as fixed monthly injection. 
Efficacy and safety of ranibizumab on subfoveal CNV with or without classic CNV secondary to 
AMD (PIER) trial showed quarterly dosing of ranibizumab after 3 monthly doses inferior to 
monthly dosing.[5] Efficacy and safety of monthly versus quarterly ranibizumab treatment in 
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neovascular age-related macular degeneration( EXCITE) trial also showed FMR to be superior to 
three monthly injections and then quarterly injections. [12] 
The open-label extension trial of ranibizumab for choroidal neovascularization secondary to 
age-related macular degeneration (HORIZON) trial showed visual acuity decreased when 
patients from the MARINA and ANCHOR trial switched to PRN dosing followed 6 monthly then 
changed to 3 monthly follow-up. [13] Safety of Ranibizumab in Subjects with Neovascular Age-
related Macular Degeneration (SAILOR) trial also showed FMR to be superior to pro re nata 
with less than monthly follow-up. [5] 
Pro re nata (PRN) with monthly follow-up 
Prospective optical coherence tomography imaging of patients with neovascular age-related 
macular degeneration treated with intraocular ranibizumab (PrONTO) study was the first 
prospective trial evaluating the use of ranibizumab in a pro re nata (PRN) approach with 
monthly follow-up for nAMD.  
At 2 years, the mean visual acuity improved by 11.1 letters (P < .001) and the OCT-CRT 
decreased by 212 μm (P < .001). These VA and OCT outcomes were achieved with an average of 
9.9 injections over 24 months. The visual acuity outcomes were similar to the landmark pivotal 
MARINA and ANCHOR trials while using fewer injections. [14] In the MARINA study at 2 years 
the 0.5mg ranibizumab group‘s mean visual acuity improved by 6.6 letters (p<0.001) and in 
ANCHOR study at 2 years the ranibizumab group’s mean visual acuity improved between 8.1 
and 10.7 letters (p<0.001).[15] 
The PrONTO study results lead to two more major clinical trials the comparison of AMD 
treatment trials (CATT) and the inhibit VEGF in age-related choroidal neovascularization (IVAN) 
trial. CATT and IVAN were designed to answer the question of which regimen was superior, 
FMR of anti-VEGF or PRN regimen of anti-VEGF with monthly follow-up. CATT and IVAN were 
also deigned to compare ranibizumab and bevacizumab.  
Bevacizumab (Avastin) is an anti-VEGF monoclonal complete antibody and is very much cheaper 
than ranibizumab. It was approved by the FDA for treatment of metastatic colon cancer in 
2004. The agent has been used off-label as a treatment option for nAMD having been shown to 
be as safe and effective in several retrospective and prospective studies including CATT and 
IVAN. Bevacizumab is by far much more cost effective option compared to ranibizumab and 
aflibercept, which was introduced later. Using only one vial of bevacizumab you can treat at 
least twenty patients with nAMD. The intravitreal injection is prepared in compounding 
pharmacies from the vial of bevacizumab.[1] 
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Fixed monthly versus Pro re nata with monthly follow-up. 
CATT was a randomized, prospective, head-to-head, non-inferiority trial comparing ranibizumab 
to bevacizumab has shown that both anti-VEGF agents have equivalent effects on visual acuity 
when administered according to the same regime. [3]  
At 1 year bevacizumab given monthly gained 8.0 letters, was as effective as ranibizumab given 
monthly with 8.5 letters gained. Bevacizumab given as PRN with monthly follow-up gained 5.9 
letters and was as effective as ranibizumab given PRN with monthly follow-up with 6.8 letters 
gained.[16]  
Ranibizumab given PRN with monthly follow-up was equal to ranibizumab monthly at 1 year 
but at 2 years monthly ranibizumab was superior to PRN with monthly follow-up with 2.4 letter 
difference between groups. At 2 years the gain in visual acuity from baseline was 8.8 letters in 
the ranibizumab group following a FMR and 7.8 letters in the bevacizumab given monthly 
group. In the ranibizumab PRN with monthly follow-up group it was 6.7 letters gained and 5.0 
letters gained in the bevacizumab PRN with monthly follow-up group.[21] 
Also switching from FMR to PRN treatment at the start of year 2 resulted in greater mean 
decrease in vision during year 2. Comparison between bevacizumab monthly and bevacizumab 
PRN with monthly follow-up was inconclusive. [15] 
IVAN was a randomized, prospective, non-inferiority trial comparing ranibizumab to 
bevacizumab given either monthly or PRN with monthly follow-up. At 1 year comparison 
between ranibizumab and bevacizumab was inconclusive. FMR was equivalent to PRN with 
monthly follow-up. [15] 
Importantly bevacizumab was equally as effective as ranibizumab in both CATT and IVAN. 
VEGF trap-eye: Investigation of efficacy and safety in wet AMD (VIEW 1 and 2) compared monthly and 
every 2 monthly dosing of aflibercept with monthly ranibizumab.  Aflibercept (Eylea) or VEGF Trap-Eye 
binds all forms of VEGF-A to D as well as Placental Growth Factor. VIEW 1 and 2 trials showed all doses 
of aflibercept dosing of 2mg every month, 0.5mg every month and 2mg every 2 months non-inferior to 
ranibizumab 0.5mg every month. [15] 
To summarize monthly ranibizumab, bevacizumab or aflibercept give similar results. PRN with 
monthly follow-up is an option but was inferior to monthly treatment at 2 years in the CATT 
study and still requires monthly follow-up. Aflibercept 2 monthly may be an alternative to FMR 
ranibizumab and bevacizumab. Aflibercept remains extremely expensive and is not a treatment 
option for the public health sector.  
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As stated earlier, bevacizumab has been proven to be as effective and safe as ranibizumab in 
major prospective randomized clinical trials and in the resource limited public health sector 





Treatment regimen options for bevacizumab 
 
At present there are three treatment regimen options for nAMD using bevacizumab: FMR, PRN 
regime with monthly follow-up and TER. FMR is the regimen adopted in the initial major trials. 
Patients are seen every month and injected every month. This regimen has proven to give the 
best visual outcome and is seen as the gold standard. Many different dosing options have been 
tried in multiple clinical trials to attempt to decrease the burden on the health sector. Quarterly 
dosing, injecting every three months, and PRN with less than monthly follow-up were shown to 
be inferior to FMR. PRN regime with monthly follow-up was shown to have results similar to 
fixed monthly but was still inferior and very importantly still requires patients to be seen 
monthly.  
 
TER is an alternative type of PRN regime that entails administering three initial injections at 
monthly intervals and then to continue monthly injections until the retina is dry as determined 
using optical coherence tomography (OCT). After the retina is dry the period between injections 
are gradually increased by 2 weeks at a time and continued injections at every visit regardless if 
retina is dry or not. Continue to extend the interval, 12 weeks usually being the maximum 
interval period of extension. If fluid accumulates again, the period between injections is 
decreased by 2 weeks at a time until a stable interval is determined for each individual patient. 
This regimen cuts down clinic visits and reduces the number of injections while it maintains 
vision similar to FMR according to results from past and ongoing clinical trials.  
 
Treat-and-extend versus PRN dosing 
In a study by Oubraham et al, TER had better gain in letters compared to PRN regimen with a 
few more injections of 8 vs 5 in the PRN group.[5]  
In a systemic review of as needed PRN regimen versus TER of ranibizumab or bevacizumab for 
nAMD, including 8 studies meeting the TER protocol and 62 studies meeting the PRN protocol 
were included. The mean visual acuity gain was 5.4 letters in the PRN group and 10.4 letters in 
the TER group. The PRN group received an average of 5.6 injections in year 1 and the TER group 
8.09. Central retinal thickness improved on average by 100.3 µm in the PRN group compared 
with 87.7 µm in the TER group. [17] 
Treat-and-extend versus fixed monthly dosing 
Two studies by Gupta et al and Shienbaum et al employed a TER of ranibizumab and 
bevacizumab respectively for treatment of nAMD with favourable visual acuity results with 
significantly fewer visits and intravitreal injections compared with treatment in a FMR.[3 and 4] 
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In a prospective TER study published in Retina in 2014 the mean visual acuity change from 
baseline was +9.5 and +8.0 letters after 12 months and 24 months respectively with a mean of 
8.6 injections in the first year and 5.6 in the second year.[18] 
The CANTREAT trial (Canadian Treat and Extend Analysis Trial with Ranibizumab) is a 
multicentre, randomized trial designed to evaluate and compare a FMR of ranibizumab to the 
TER approach in achieving and maintaining a maximum visual acuity. It is theorized that the TER 
will be non-inferior to monthly dosing in terms of mean change in visual acuity from baseline to 
1 year while decreasing the number of injections in the TER. It is expected that the TER 
approach will allow for proactive, individualized treatment compared to PRN reactive 
treatment, giving better results than PRN regimen in terms of visual acuity. [19] 
Interim data from the CANTREAT trial showed the mean visual acuity gain was 6.8 letters in the 
FMR arm and 7.2 letters in the TER arm at 1 year. Patients in the FMR arm and TER arms 
received an average of 11.9 and 9.9 injections respectively at 12 months. [20] 
What other benefits are there of fewer intravitreal injection of Anti-VEGF? 
Endophthalmitis is a major risk factor with intravitreal injection with devastating visual 
consequences. Retrospective studies have reported that the incidence of post intravitreal 
injection endophthalmitis ranges from 0.02 to 1.6%. Multiple recent large meta-analysis reports 
indicate the incidence rates between 0.049 to 0.056%. Although the rate of endophthalmitis is 
low for any individual patient the potential incidence rises when receiving repeated monthly 
injections.[22] 
 It is a logical assumption if we can decrease the number of intravitreal injections needed by a 
patient we can decrease the risk of endophthalmitis. 
Other ocular complications include non-infectious inflammation to the biologic anti-VEGF 
agents, retinal tears and detachment, retinal pigment epithelium rip, elevated intraocular 
pressure post intravitreal injection and cataract. [23] 
Evidence suggesting that receiving more anti-VEGF injections is associated with geographic 
atrophy progression comes from numerous studies. Geographic atrophy was the main reason 
of decreased vision in patients receiving intravitreal anti-VEGF in the MARINA trial. [23] The 
SEVEN-UP study observed geographic atrophy progression in nAMD patients treated with 
ranibizumab over a mean of 7.4 years. The CATT trial found that patients treated with monthly 
anti-VEGF intravitreal injection had higher rate of geographic atrophy progression than the 
patients treated with the PRN regimen with monthly follow-up. [24] 
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Systemic safety profile of intravitreal anti-VEGF is not known to date with confounding 
evidence and persistently unanswered questions. As is well known, VEGF is a potent promoter 
of vascular hyper-permeability. Anti-VEGF agents significantly reduce vascular hyper-
permeability, and when given systemically can raise systemic arterial blood pressure. 
Systemically delivered anti-VEGFs are known to promote the development of arterial 
thrombotic events but this has been observed at much larger doses than intravitreal injection 
of anti-VEGF. [23] 
There have been no statistically significant evidence derived from the numerous studies that 
intravitreal injection of anti-VEGF leads to increased development of arterial thrombotic events 
however these clinical trials were not statistically powered to answer this question. Subgroup 
analysis and pharmacokinetic data points to the possibility of a risk of arterial thrombotic 
events from intravitreal anti-VEGF drugs. The populations at the highest risk for arterial 
thrombotic events based upon available clinical trial data, clinical experience and theoretical 
factors are diabetics, patients 85 years and older and patients with history of prior strokes. [23] 
It is therefore reasonable to want to decrease the number of intravitreal anti-VEGF injections 







While clinical trials are ongoing with novel therapies to decrease the number of office visits and 
intravitreal injections a TER has been shown in other clinical trials to be as effective as the gold 
standard of FMR and may be superior to PRN regime. TER reduces the number of office visits as 
well as the number of intravitreal injections and at the same time potentially decreasing the 
risk of complications and side-effect from intravitreal injection of anti-VEGF. Bevacizumab off 
label is far cheaper than ranibizumab and it is essential to investigate the visual outcomes and 
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Bevacizumab in a treat-and-extend regimen for 
neovascular age related macular degeneration in a 
resource limited sector 
 
Objective: To obtain the clinical outcomes of patients using intravitreal bevacizumab with a 
treat-and-extend regimen for neovascular age-related macular degeneration (nAMD) and 
determine if this regime will benefit resource limited sectors in managing these patients. 
Design: A retrospective chart review of patients who received intravitreal bevacizumab for 
nAMD between June 2011 and June 2016.  
Subjects: 53 eyes of 48 patients, 1 year follow-up (n=53) and 2 year follow-up (n=24). 
Methods: Patients were diagnosed with nAMD using fundus fluorescein angiography and 
optical coherence tomography at the first visit. Patients initiated on treatment followed a treat-
and-extend treatment protocol.  
Main outcome measures: Main outcome measures was mean change from baseline visual 
acuity (VA) at year 1 and 2, mean change from baseline central retinal thickness (CRT) at year 1 
and 2, mean number of intravitreal bevacizumab injections at year 1 and 2 and mean period of 
extension between intravitreal bevacizumab injections. 
Results: Mean VA at start of treatment was 0.21 and improved to 0.38 year 1 and 0.45 year 2. 
The mean CRT at the start of the study was 333.46 µm and improved to 265.35 µm at year 1 
and 245.79µm at year 2. The mean number of injections in year 1 was 9.64 and 6 in year 2. The 
mean number of weeks between injections year 1 was 5.59 and 8.58 in year 2.  
Conclusion: In this study it was ascertained that patient’s VA did improve significantly from 







The current standard of care for neovascular age-related macular degeneration (nAMD) is 
intravitreal injection of an anti-vascular endothelial growth factor (anti-VEGF). Monthly 
injection places an enormous burden on the health system and on the patients themselves.   
 
It has long been known that patients respond differently to anti-VEGF therapy and not all 
patients need monthly injection. In an attempt to decrease the burden on the health sector and 
patients many different treatment regimens have been tried and tested in clinical trials to 
decrease clinic visits as well as the number of injections received by patients with varying 
results. 
 
Intravitreal injection of anti-VEGF is not without risk, such as the risk of endophthalmitis, 
serious adverse systemic events and evidence of progression of geographic atrophy with 
repeated injections.[1,2] 
 
At present there are three treatment regimen options for nAMD using bevacizumab. Fixed 
monthly injection regimen (FMR), Pro re nata (PRN) regime with monthly follow-up, and treat-
and-extend regimen (TER). 
 
FMR was adopted in the initial major trials. Patients are seen every month and injected every 
month. This regimen has proven to give the best visual outcome and is seen as the gold 
standard. Many different dosing options have been tried in multiple clinical trials to attempt to 
decrease the burden on the health sector but were shown to be inferior to a FMR. PRN with 
monthly follow-up was shown to have results similar to FMR but was still inferior and very 
importantly still requires patients to be seen monthly. TER is an alternative type of PRN regime 
that entails administering three initial injections at monthly intervals and then to continue 
monthly injections until the retina is dry as determined using optical coherence tomography 
(OCT). After the retina is dry the period between injections are gradually increased by 2 weeks 
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at a time and continued injections at every visit regardless if retina is dry or not. Continue to 
extend the interval between injections, 12 weeks is usually the maximum interval period of 
extension. If fluid accumulates again the period between injections is decreased by 2 weeks at a 
time until a stable interval is determined for each individual patient. 
 
The reason for this study was to determine the clinical outcomes of patients using intravitreal 
bevacizumab (BVZ) with a TER for nAMD and determine if this regime will benefit resource 
limited sectors in managing these patients. Evidence in the literature is growing that a TER is as 
effective in restoring and maintaining vision as the current gold standard of FMR and more 
effective than a PRN with monthly follow-up, with fewer injections and fewer office visits. 
Interim 1 year data from the Canadian Treat and Extend Analysis Trial with Ranibizumab 
(CANTREAT), showed the mean visual acuity gain was equivalent in the TER arm compared to 
the FMR despite fewer injections.[3]  
 
A retrospective chart review was undertaken of all patients with nAMD that presented to Inkosi 
Albert Luthuli Central Hospital (IALCH) where electronic patient records were kept. 53 eyes of 
48 patients met the entry criteria from June 2011 until June 2016. In this paper we are able to 
show that a TER may be a safe and cost-effective alternative to the current gold standard of 
fixed monthly injection of an anti-VEGF for nAMD adding to the growing body of evidence in 









Charts of all patients diagnosed with nAMD at IALCH during the period of June 2011 until June 
2016 with at least 1 year follow-up were reviewed and included in this study.  
 
The inclusion criteria included all patients with nAMD diagnosed using fluorescein angiography 
(FA) and optical coherence tomography (OCT) and treated according to the TER using the anti-
VEGF bevacizumab.  
 
All other causes of choroidal neovascularization such as dominant drusen, angioid streaks, 
polypoidal choroidal vasculopathy etc. were excluded from the patient cohort.  
 
Fifty three eyes from forty eight patients, with fifty three having 1 year follow-up and twenty 
four having 2 year follow-up were included.  
 
Visual acuity (VA) and central retinal thickness (CRT) was obtained at the first visit, at year 1 and 
at year 2. Total number of injections in year 1 and year 2 was obtained as well as the interval 
period between each injection.   
Mean change from baseline VA at year 1 and 2, mean change from CRT at year 1 and 2, mean 
number of intravitreal bevacizumab injections in year 1 and 2 and mean period of between 




Data were entered into Statistical Packages for the Social Sciences for analysis (SPSS). A one-
sample t-test was used to assess the differences in VA at year 1 and year 2 and central retinal 






As this was a retrospective chart review, informed consent was not obtained from patients 
included in this study. No patient contact was made and site permission was obtained from 
Inkosi Albert Luthuli Hospital management. Institutional Review Board and Ethics committee 
approval was obtained from the University of KwaZulu-Natal Biomedical Research Ethics 







Of the 48 patients in the study more than 90% were above the age of 70y. [Table 1] Age is one 
of the most important risk factors for the development of nAMD.[4] 
 
Age (years) Frequency Percent 
 < 70 4 7.5 
70 - 74 9 17.0 
75 - 79 13 24.5 
80 - 84 16 30.2 
≥ 85 11 20.8 
Total 53 100.0 
Table 1: Age 
 
Of the 53 study eyes, 29 were from male patients.[Table 2] 
 
Sex Frequency Percent 
 Female 24 45.3 
Male 29 54.7 
Total 53 100.0 
Table 2: Sex 
 
Race Frequency Percent 
 Black 3 5.7 
Indian 8 15.1 
White 42 79.2 
Total 53 100.0 
Table 3: Race 
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The majority of patients were of European descent. [Table 3] nAMD has a strong genetic 




N Minimum Maximum Mean 
Std. 
Deviation Skewness 
Statistic Statistic Statistic Statistic Statistic Statistic 
Std. 
Error 
VA_Start 53 0.01 0.80 0.21 0.174 1.637 0.327 
VA_1year 53 0.10 1.00 0.38 0.267 0.846 0.327 
VA_2year 24 0.10 1.00 0.45 0.266 0.519 0.472 
        
Table 4: Visual Acuity 
VA_Start = Visual acuity at the Start of Treatment.  
VA_1year/2year = Visual Acuity at Year 1 and Year 2.  
 
 
The visual acuity was recorded in the decimal system for ease of recording and statistical 
analysis. A VA of counting fingers was given a decimal score of 0.01. Data on VA at the start of 
treatment was available for 53 eyes, 53 eyes at year 1 and 24 eyes at year 2.  
 
 
The best VA recorded was 1.0 and 0.01 the worst VA recorded. Mean VA at start of treatment 
was 0.21 and improved to 0.38 at year 1 and 0.45 at year 2.[Table 4] Final mean visual acuity 
converted to a visual acuity score (VAS) was done to be able to determine number of letters 
gained. Mean VAS at the start of treatment was 66, at year 1 was 79 with 13 letters gained and 






N Minimum Maximum Mean 
Std. 
Deviation Skewness 
Statistic Statistic Statistic Statistic Statistic Statistic Std. Error 
CRT_Start 48 215.0 611.0 333.46 85.443 1.160 0.343 
CRT_1year 48 134.0 774.0 265.35 93.555 3.528 0.343 
CRT_2year 24 172.0 349.0 245.79 49.773 0.494 0.472 
        
Table 5: Central Retinal Thickness 
CRT_Start = Central Retinal Thickness at the Start of Treatment.  
CRT_1/2 = Central Retinal Thickness at Year 1 and Year 2. 
 
 
Central retinal thickness (CRT) was measured using optical coherence tomography (OCT). Data 
on central retinal thickness of 48 eyes was available at the start of treatment and 48 eyes at 
year 1 and 24 eyes at year 2. The mean CRT at start of the study was 333.46 µm and improved 




 Total Number of Injections Number of Eyes Mean Number of Injections 
Year 1 511 53 9.64 
Year 2 144 24 6 
Table 6: Number of Injections 
 
The mean number of injections in year 1 was 9.64 per eye and in year 2 the mean number of 






The mean number of weeks between injections in year 1 was 5.59 and 8.58 in year 2. [Table 7] 
 
 
 Mean Number of Weeks Between Injections Std. Deviation 
Year 1 5.59 1.18 
Year 2 8.58 3.13 







In this study it was ascertained that patient’s vision did improve significantly from baseline at 
year 1 and 2. Central retinal thickness improved significantly at year 1 and year 2 and the 
average number of injections was less than with FMR and similar to other TER regimens. 
 
Because this was a retrospective chart review a decimal system was used to record vision in the 
patients charts using a standard Snellen chart and this visual acuity was used in our study. 
Most, if not all studies conducted in the literature, uses the Early Treatment of Diabetic 
Retinopathy Study (ETDRS) chart and ETDRS protocol. This is considered to represent the gold 
standard for VA measurements.[5] 
 
The ETDRS protocol was not followed in our study but to be able to compare our results with 
the landmark clinical trials we converted our final mean VA into a visual acuity score (VAS). 
With the VAS we are able to determine the number of letters gained in VA and compare our 
results to other trials where the VAS scale was calculated on ETDRS charts, where 1 point is 
credited for each letter read correctly. 
 
The Minimally classic/occult trial of the anti VEGF antibody Ranibizumab in the treatment of 
Neovascular ARMD (MARINA) and Anti-VEGF antibody for the treatment of predominantly 
classic choroidal neovascularization in AMD (ANCHOR) trials  were the landmark clinical trials 
and demonstrated significant visual gain for the first time in the history of treatment of nAMD. 
In MARINA and ANCHOR patients followed a FMR with injections every month for two years. 
 
Fixed Monthly Regimen 
 
In the MARINA study at 2 years the 0.5mg ranibizumab group‘s mean VA improved by 6.6 
letters (p<0.001) and in ANCHOR study at 2 years the ranibizumab group’s mean VA improved 




Subsequent studies followed MARINA and ANCHOR which aimed at reducing frequency of 
injections. Monthly intravitreal injection is a major burden on patients and the health system.  
 
Less than monthly follow-up 
 
Alternative fewer fixed scheduled injections have not resulted in visual outcomes that were as 
favourable as a FMR.  
 
Efficacy and safety of ranibizumab on subfoveal CNV with or without classic CNV secondary to 
AMD (PIER) trial showed quarterly dosing of ranibizumab after 3 monthly doses inferior to a 
FMR.[6]  
 
Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-
related macular degeneration (EXCITE) trial also showed a FMR to be superior to three monthly 
injections and then quarterly injections. [12] 
 
The open-label extension trial of ranibizumab for choroidal neovascularization secondary to 
age-related macular degeneration (HORIZON) trial showed VA decreased when patients from 
the MARINA and ANCHOR trial switched to PRN dosing. [13]  
 
Safety of Ranibizumab in Subjects with Neovascular Age-related Macular Degeneration 
(SAILOR) trial also showed FMR to be superior than PRN with less-than-monthly follow-up.[6] 
 
Pro re nata with monthly follow-up 
 
Prospective optical coherence tomography imaging of patients with neovascular age-related 
macular degeneration treated with intraocular ranibizumab (PrONTO) study was the first 
prospective trial evaluating the use of ranibizumab in a PRN approach with monthly follow-up 
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for nAMD. At 2 years, the mean visual acuity improved by 11.1 letters (P < .001) and the OCT-
CRT decreased by 212 μm (P < .001). These VA and OCT outcomes were achieved with an 
average of 9.9 injections over 24 months. The visual acuity outcomes were similar to the pivotal 
landmark MARINA and ANCHOR trials while using fewer injections. [14]  
 
Fixed monthly versus Pro re nata with monthly follow-up 
 
The PrONTO study results lead to two more major clinical trials, the comparison of AMD 
treatment trials (CATT) and the inhibit VEGF in age-related choroidal neovascularization (IVAN) 
trial.  
 
CATT and IVAN were designed to answer the question of which regimen was superior, FMR or 
PRN with monthly follow-up. CATT and IVAN were also deigned to compare the therapeutic 
efficacy of the molecules ranibizumab and bevacizumab.  
 
Bevacizumab (Avastin) is an anti-VEGF monoclonal complete antibody and is very much cheaper 
than ranibizumab. It was approved by the FDA for treatment of metastatic colon cancer in 
2004. The agent has been used off-label as a treatment option for nAMD having been shown to 
be as safe and effective in several retrospective and prospective studies including CATT and 
IVAN. Bevacizumab is by far much more cost effective option; using only one vial of 
bevacizumab you can treat at least twenty patients with nAMD. The intravitreal injection is 
prepared in compounding pharmacies from the vial of bevacizumab.[4] 
 
CATT was a randomized, prospective, head-to-head, non-inferiority trial comparing ranibizumab 
to bevacizumab has shown that both anti-VEGF agents have equivalent effects on visual acuity 
when administered according to the same regime. [8]  
 
At 1 year bevacizumab given monthly gained 8.0 letters, was as effective as ranibizumab given 
monthly with 8.5 letters gained. Bevacizumab given as PRN with monthly follow-up gained 5.9 
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letters and was as effective as ranibizumab given PRN with monthly follow-up with 6.8 letters 
gained.[15]  
 
Ranibizumab given PRN with monthly follow-up was equal to ranibizumab given with a FMR at 
1 year but at 2 years monthly ranibizumab was superior to PRN with monthly follow-up with a 
2.4 letter difference between groups.  
 
At 2 years the gain in visual acuity from baseline was 8.8 letters in the ranibizumab given with a 
FMR and 7.8 letters in the bevacizumab given with a FMR. In the ranibizumab given PRN with 
monthly follow-up group it was 6.7 letters gained and 5.0 letters gained in the bevacizumab 
given PRN with monthly follow-up.[16] Also switching from a FMR to a PRN treatment regimen 




In our study the mean VAS at the start of treatment was 66, at year 1 it was 79 with 13 letters 
gained and 83 at year 2 with 17 letters gained. The mean number of injections in year 1 was 
9.64 per eye and in year 2 the mean number of injections was 6. The mean number of weeks 
between injections in year 1 was 5.59 and 8.58 in year 2. These results are very comparable to 
results in a prospective treat-and-extend study published in Retina in 2014.[11] The mean visual 
acuity change from baseline was 9.5 at year 1 and 8.0 letters at year 2 with a mean of 8.6 
injections in year 1 and 5.6 injections in year 2 in this study. 
 
Treat-and-extend versus pro re nata with monthly follow-up 
 
In a study by Oubraham et al [6], a TER had better gain in letters compared to a PRN regimen 




In a systemic review meta-analysis of as needed PRN regimen versus TER’s of ranibizumab or 
bevacizumab for nAMD, 8 studies met the TER protocol and 62 studies met the PRN protocol  
were included. The mean VA gain was 5.4 letters in the PRN group and 10.4 letters in the TER 
group in year 1. The PRN group received an average of 5.6 injections in year 1 and the TER 
group 8.09. This compared to our gain of 13 letters in year 1 and to our mean number of 
injections in year 1 of 9.64. Central retinal thickness improved on average by 100.3 µm in the 
PRN group compared with 87.7 µm in the TER group compared to our study of 68.1 µm at year 
1. [7] 
 
Treat-and-extend versus fixed monthly regimen 
 
Two studies by Gupta et al and Shienbaum et al [8 and 9] employed a TER of ranibizumab and 
bevacizumab respectively for treatment of nAMD with favourable VA results with significantly 
fewer visits and intravitreal injections compared with treatment in a FMR. 
 
The Canadian Treat and Extend Analysis Trial with Ranibizumab (CANTREAT) is the first 
multicentre, randomized trial designed to evaluate and compare head-to-head a FMR dosing of 
ranibizumab to the TER approach in achieving and maintaining maximum VA.  
 
Interim data from the CANTREAT trial showed the mean visual acuity gain was 6.8 letters in the 
FMR dosing arm and 7.2 letters in the TER dosing arm at 1 year. Patients in the FMR dosing arm 
and TER dosing arms received an average of 11.9 and 9.9 injections respectively at 12 months. 
[3] 
 
What other benefits of fewer intravitreal injection of Anti-VEGF? 
 
Endophthalmitis is a major risk factor with intravitreal injection with devastating visual 
consequences. Retrospective studies have reported that the incidence of post intravitreal 
injection endophthalmitis ranges from 0.02 to 1.6 %. Recent large meta-analyses report the 
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incidence rates between 0.049 to 0.056 %. Although the rate of endophthalmitis is low for any 
individual patient the potential incidence rises when receiving repeated monthly injections.[17] 
Other ocular complications include non-infectious inflammation to the biologic anti-VEGF 
agents, retinal tears and detachment, retinal pigment epithelium rip, elevated intraocular 
pressure post intravitreal injection and cataract. [19] 
 
Evidence suggesting that receiving more frequent anti-VEGF injections is associated with 
geographic atrophy progression comes from numerous studies. Geographic atrophy was the 
main reason of decreased vision in patients receiving intravitreal anti-VEGF in the MARINA 
trial.[18]  
 
The SEVEN-UP study observed geographic atrophy progression in nAMD patients treated with 
ranibizumab over a mean of 7.4 years. The CATT trial found that patients treated with monthly 
anti-VEGF intravitreal injection had higher rate of geographic atrophy progression than the 
patients treated with the PRN with monthly follow-up regimen. [19] 
 
Systemic safety profile of intravitreal anti-VEGF is not known to date with confounding 
evidence and persistently unanswered questions. As known VEGF is a potent promoter of 
vascular hyper-permeability. Anti-VEGF agents significantly reduce vascular hyper-permeability, 
and when given systemically can raise systemic arterial blood pressure. Systemically delivered 
anti-VEGF is known to promote the development of arterial thrombotic events but this has 
been observed at much larger doses than intravitreal injection of anti-VEGF. [19] 
 
There have been no statistically significant evidence derived from the numerous studies that 
intravitreal injection of anti-VEGF leads to increased development of arterial thrombotic events, 
however these clinical trials were not statistically powered to answer this specific question. 
Subgroup analysis and pharmacokinetic data points to the possibility of a risk of arterial 




The populations at the highest risk for arterial thrombotic events based upon available clinical 
trial data, clinical experience and theoretical factors are diabetics, patients 85 years and older 
and patients with history of prior strokes. [19]  
 
It is therefore reasonable to want to decrease the number of intravitreal anti-VEGF injections 
and extend the period between intravitreal anti-VEGF injections. 
 
Limitations of the study 
 
Being a retrospective chart review is a limitation in itself. It was also noticed while collecting the 
data that there was poor compliance with the TER protocol at IALCH, resulting in many patients 
not following an absolute and strict TER. One reason that contributed to this was most probable 
due to poor follow-up by patients due to social circumstances, such as finance or transport 
issues. More importantly also determined from review of the charts was clinician error when 
deciding on intravitreal injection frequency.  
 
This resulted in a mixture of a TER and PRN regimen being followed in many patients at IALCH. 
The results are a more realistic real world experience which has shown that our treatment is 
effective in treating nAMD however following a TER is not difficult and should easily be adhered 
to with possible better visual acuity results, fewer clinic visits and fewer injections of intravitreal 
anti-VEGF.  
 
Areas identified where intervention would make a difference include education of treating 
ophthalmologists, especially the junior registrars and medical officers, on the TER protocol: 
Educating patients on the importance of follow-up on correct clinic appointments and the need 
for close monitoring of patients’ response to treatment. The possibility of down referring 
patients back to base ophthalmology clinics with the adequate staff and equipment for 
management of nAMD patients. This would be more convenient for the patients as IALCH 
ophthalmology clinic is only one of two clinics in KwaZulu-Natal currently providing intravitreal 
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injection of bevacizumab for nAMD and many patients travel a great distance for their clinic 
appointments. 
 
The results from our study show our VA gain being better than most other studies. The reason 
is that we did not use the ETDRS charts and ETDRS protocol as most prospective studies did. 
The VA in our study was recorded by the nursing staff using standard Snellen charts by different 
nursing staff at each visit in a relatively uncontrolled environment.  
 
In a study comparing VA determined by an ETDRS chart versus a Snellen chart the visual acuity 
scores were significantly better with the ETDRS charts when compared to Snellen charts. The 
greatest difference was with poor visual acuity and in patients with nAMD. [5] 
 
Potentially the ETDRS patients in the prospective studies had better initial mean VA and 









This retrospective chart review has shown that our current treatment for nAMD is resulting in 
significant visual gains comparable to major prospective trials.  
 
Interim data form the first head-to-head study comparing a TER to the gold standard of a FMR, 
CANTREAT, has shown very promising results showing a TER is at least effective as a FMR.  
 
At IALCH implementation of a TER protocol was done early because of paucity of resources and 
personnel and this study has shown that IALCH in not delivering sub-standard care for patients 
with nAMD but our implementation of the TER can be followed more strictly.  
 
This was a small study but VA gains are similar to that with a FMR with fewer injections and 
fewer follow-up visits, adding to the growing body of evidence in favour of a TER for the 
treatment of nAMD.  
 
 











Mean VA_1y 11.3 7.2 8.5 8.0 6.8 
Mean VA_2y 10.7 6.6 8.8 7.8 - 
Number Inj_1y 13 13 - - 11.9 
Number Inj_2y 12 12 - -  
CRT_1y - - 196 - - 
CRT_2y - - - - - 
Table 8: Fixed Monthly Dosing Studies 
 




With fewer injections we can also potentially decrease the risk of complications such as 
endophthalmitis, cataract, progression of geographic atrophy and arterial thrombotic events 
from intravitreal injection of anti-VEGF. 
 
 









Mean VA_1y 6.8 5.9 9.3 5.4 
Mean VA_2y 6.7 5.0 11.1 - 
Number Inj_1y - - 5.6 5.6 
Number Inj_2y - - - - 
CRT_1y - - 178 100.3 
CRT_2y - - - - 
Table 9: PRN Dosing With Monthly Follow-up Studies 
BVZ – Bevacizumab. RBZ – Ranibizumab.  
 
 








Mean VA_1y 10.4 9.5 7.2 13 
Mean VA_2y - 8.0 - 17 
Number Inj_1y 8.1 8.6 9.9 9.64 
Number Inj_2y  5.6 - 6 
CRT_1y 87.7 - - 68.1 
CRT_2y - - - 87.7 
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The Guidelines for Authorship for African Vision 
and Eye Health Journal 
 
Submit original work to the African Vision and Eye Health ↑ 
We ask our authors to ensure that they submit original work that: 
• have been honestly carried out according to rigorous scientific standards that has not been 
obtained fraudulently or dishonestly, or fabricated or falsified 
• present an accurate account of the research performed and the results obtained and offer an 
objective discussion of the significance thereof 
• present sufficient detail and reference to public sources of information in order to permit 
peers to repeat the work if needed 
• report data accurately and never ‘fudged’, with any problematic data also treated accordingly 
• cite all relevant references; it is the duty of the author to check the references that are cited 
very carefully to ensure that the details are accurate and in the correct format 
• declare any (potential) conflicts of interest 
• do not claim originality if others have already reported similar work in part or as a whole 
• give credit to the work and findings of others that have led to your findings or influenced 
them in some way 
• identify any hazards inherent in conducting the research 
• do not contain plagiarised material or anything that is libellous, defamatory, indecent, 
obscene or otherwise unlawful and that the work does not infringe on the rights of others 
• provide all the statements required by the journal in order to prove that the experimental 
protocols were approved appropriately and that they meet all the guidelines of the agency 
involved, including obtaining informed consent where required if investigations have 
involved animals or human subjects 
• contain explicit permission of the individuals from whom information was privately obtained 
and that they have accompanying appropriate letters confirming permission to include this 
information , as may be acquired by journals 
• avoid fragmenting research to maximise the number of articles submitted, also known as 
‘salami publishing’ 
• have not been submitted to multiple journals or other publication media. 
Although an experimental or theoretical study may sometimes justify criticism of the work of 
another scientist, in no circumstances is personal criticism appropriate. Do not present work, 
or use language, in a way that detracts from the work or ideas of others. 
Cover page: The format of the compulsory cover letter forms part of your submission and is 
located on the first page of your manuscript and should always be presented in English. You 
should provide all of the following elements: 
• Article title: Provide a short title of 50 characters or less. 
• Significance of work: Briefly state the significance of the book being reported on. 
• Full author details: Title(s), Full name(s), Position(s), Affiliation(s) and contact details 
(postal address, email, telephone and cellphone number) of each author.  
• Corresponding author: Identify to whom all correspondence should be addressed to.  
• Authors’ contributions: Briefly summarise the nature of the contribution made by each of 
the authors listed. 
• Summary: Lastly, a list containing the number of words, pages, tables, figures and/or other 
supplementary material should accompany the submission.  
Formatting requirements: Please use British English, that is, according to the Oxford 
English Dictionary. Avoid Americanisms (e.g. use ‘s’ and not ‘z’). Consult the Oxford 
English Dictionary when in doubt and remember to set your version of Microsoft Word to 
UK English. 
• Language: Manuscripts must be written in British English. 
• Line numbers: Insert continuous line numbers. 
• Font: 
o Font type: Palatino  
o Symbols font type: Times New Roman  
o General font size: 12pt  
• Line spacing: 1.5 
• Headings: Ensure that formatting for headings is consistent in the manuscript. 
o First headings: normal case, bold and 14pt 
o Second headings: normal case, underlined and 14pt 
o Third headings: normal case, bold and 12pt 
o Fourth headings: normal case, bold, running-in text and separated by a colon. 
Our publication system supports a limited range of formats for text and graphics. Text files 
can be submitted in the following formats only: 
• Microsoft Word (.doc): We cannot accept Word 2007 DOCX files. If you have created your 
manuscript using Word 2007, you must save the document as a Word 2003 file before 
submission. 
• Rich Text Format (RTF) documents uploaded during Step 2 of the submission process. Users 
of other word processing packages should save or convert their files to RTF before 
uploading. Many free tools are available that will make  this process easier. 
Publisher House Style for authors 
Please select the applicable link below: 
• Language usage 
• Tables, figures and photographs 
• Guidelines for Math 
• Unicode fonts 
Fonts: Please use standard (UNIcode) fonts such as Palatino, Times New Roman, Helvetica 
and Symbol. Fonts that have not been embedded will usually be replaced by Courier, 
resulting in character loss or realignment. 
Creatives: Please supply images as the size intended for final publication. Resizing of images 
is time consuming and can result in loss of quality. 
Language usage ↑ 
General elements 
• Quotations: Use single quotation marks for quotations. For quotations within quotations, use 
double quotation marks. Quotations of more than 30 words are to be indented. Do not use 
quotation marks for indented quotations unless it is direct speech (e.g. interviewee 
responses). 
• En dashes and hyphens: Use an en dash (i.e. extended hyphen that can be found in the 
Insert box under Symbols in Microsoft Word) in ranges of numbers and dates. Use hyphens 
only for words that are hyphenated. 
• Dates: Format dates as ‘02 October 2006’, except at the beginning of sentences where 
numerals and dates should either be spelt out or the sentence should be rearranged. 
• Percentage: The per cent symbol (%) is used in conjunction with all numbers (e.g. 12%). 
Numbers that have been written out will appear with ‘per cent’ (e.g. five per cent). 
'Percentage' is used in a general sense. 
• Numbers: Numbers from one to nine must be written out. Numbers from 10 onwards, must 
be used as numerals, except at the beginning of a sentence. 
• Spacing and punctuation: There should be one space (and not two) between sentences; one 
space before unit terms (e.g. 5 kg, 5 cm, 5 mmol, 5 days, 5 °C, etc.), but no space before the 
percentage symbol (%). Thousands and millions are marked with a space and not a comma 
(e.g. 1000,    1 000 000). Ranges are expressed with an extended hyphen (i.e. en dash), not 
with a short hyphen (e.g. 1990–2000). 
• Units: The use of units should conform to the SI convention and be abbreviated accordingly. 
Metric units and their international symbols are used throughout, as in the decimal point (not 
the decimal comma), and the 24-hour clock. 
• Foreign language: Foreign language words should be italicised, unless these words are part 
of normal usage. Consult the Oxford English Dictionary if in doubt. 
• Acronyms: If a phrase with an established acronym or abbreviation is used and appears more 
than five times in your article, please include the acronym or abbreviation in brackets after 
first mention of the phrase, and then use the acronym or abbreviation only. Please note that 
you should not define acronyms or abbreviations in any of your headings. If either has been 
used in your abstract, you need to define them again on their first usage in the main text. 
Sensitive and political terms 
• Race and ethnicity: Try to avoid terms such as 'Blacks' and 'Whites' (please note the use of 
uppercase letters); use instead ‘Black people’, ‘White people’, etc. 'Caucasian', 'Mongoloid', 
'Negroid', etc. are generally to be avoided except in human population studies. 'Mixed race' is 
preferable to 'half-caste' or 'Coloured'. 
• Disabilities: Avoid using ‘the disabled’, ‘the handicapped’, and instead use  'people with 
disabilities not 'the disabled' or 'people with learning difficulties’, not 'mentally handicapped'. 
• Disease 
o Avoid health-determined categorisation. 
 Use ‘people with diabetes’; not ‘diabetics’. 
 Use ‘people with cancer’; not ‘cancer sufferers’. 
 Use ‘sexually transmitted infection (STI)’ and not ‘sexually transmitted disease (STD)’. 
o Avoid phrasing that dehumanises a patient. Many authors use case (instance of a disease) 
when they mean patient (i.e. the person or individual who is ill with the (disease). 
• AIDS 
o Ensure that ‘AIDS’ is used for the disease and ‘HIV’ for the  virus, e.g. do not use ‘AIDS 
carrier’, ‘AIDS positive’, ‘AIDS virus’ or ‘catching AIDS or HIV/AIDS’ (avoid using the 
solidus here).   
o ‘AIDS sufferer/victim’ is inappropriate; use ‘people with AIDS’.   
o Refer to ‘people who practise high-risk activities’ and not ‘high-risk groups’. 
o The expression ‘full-blown AIDS’ is unnecessary if the correct distinction has been made 
between HIV and AIDS.  
• Male versus Female 
o ‘Male’ and ‘female’ are adjectives, so be careful to use them as such (i.e. a male patient and 
a female frog, but a 35-year-old man, a French woman and a group of 25 men and 
35 women).   
• Sexuality: Avoid the terms ‘homosexual activities’ (if achievable within the manuscript’s 
context, specify which activity is being referred to, especially when dealing with medical 
research.) Avoid using ‘homosexuals’ (specify homosexual men or homosexual women).  
• Gender: Use gender neutral nouns. Avoid the use of ‘man’ if not specifically referring to 
men; for example:  
o for ‘man’ use ‘humans’  
o for ‘man-kind’ use ‘the human race’   
o for ‘man-power’ use ‘workforce’   
o for ‘man-made fibre’ use ‘synthetic fibre’  
• ‘He/she’, ‘him/her’ and ‘his/hers’: For ‘he/she’, ‘him/her’ and ‘his/hers’ rather use 
‘he or she’, ‘her or him’, ‘his or hers’ (without a solidus) or change to plural ‘they’. Use 
inclusive pronouns: use ‘he or she’, or rephrase the sentence (rephrasing to the plural form 
often works):  
✗ … Any observer of changes in publishing technology will perceive that he has need of…  
✓ … Observers of… will perceive that they have… 
Beware of referring to people with stereotypical pronouns (e.g. ‘the doctor 
treated his patient’; ‘the secretary tidied her desk’). 
• Geography 
o The terms Third World, poor countries and underdeveloped countries should be avoided. 
o Developing or non-developed country/society is better, but it is best to specify countries or 
regions instead. 
o Western society and Western World should only be used in relation to geography; otherwise, 
use developed world/society or, even better, specify the countries themselves or the region.  
Tables, figures and photographs ↑ 
In Step 4 of the online submission process, upload all tables, figures, images, and 
supplementary files. Tables should be saved and uploaded as separate Excel (.xls) files with 
no more than 10 figures and tables in total per article. Ensure that all personal identifying 
information is removed from the supplementary files as indicated in the provided 
instructions. All captions should be provided together on a separate page. Tables and figures 
should use numerical numbers. 
• Organise your visual presentation: Once you have read through the analyses and decided 
how best to present each table or figure, think about how you will arrange them within the 
article. The analyses should tell a story’ that leads the reader through the steps needed to 
logically answer the question(s) that you as author are posing in the Introduction. The order 
in which you present the results can be as important in convincing the readers as what you 
actually are saying in the text. 
• How to refer to tables and figures in the text: Every figure and table included in the 
paper must be referred to in the body of the text. Use sentences that draw the reader's 
attention to the relationship or trend you wish to highlight, referring to the appropriate figure 
or table only in parenthesis e.g.: 
o Germination rates were significantly higher after 24 h in running water than in controls 
(Figure 4). 
o DNA sequence homologies for the purple gene from the four congeners (Table 1) show high 
similarity, differing by at most 4 base pairs. (Avoid sentences that give no information other 
than directing the reader to the figure or table, e.g. Table 1 shows the summary results for 
male and female heights at Bates College.) 
• Abbreviation of the word ‘Figure’:  When referring to a figure in the text, the word ‘figure’ 
is never abbreviated as ‘Fig.’; the same rule applies to the usage of ‘table’. Both words are 
spelled out completely in descriptive legends.  
• How to number tables and figures: Figures and tables are numbered independently, in the 
sequence in which you refer to them in the text, starting with Figure 1 and Table 1. If, in 
revision, you change the presentation sequence of the figures and tables, you must renumber 
them to reflect the new sequence. 
• The acid test for tables and figures: Any table or figure you present must be clear, well-
labelled, and described by its legend to be understood by your intended audience without 
reading the results section. That is, it must be able to stand alone and be  interpretable. Overly 
complicated figures or tables may be difficult to understand in or out of context, so strive for 
simplicity whenever possible.  
• Descriptive legends or captions: To pass the acid test above, a clear and complete legend 
(sometimes called a caption) is essential. Like the title of the article itself, each legend should 
convey as much information as possible about what the table or figure intends to tell the 
reader: 
o the results that are being shown in the graph(s), including the summary statistics plotted  
o the organism studied in the experiment (if applicable) 
o a context for the results: the treatment applied or the relationship displayed, etc.  
o location (only if a field experiment) 
o specific explanatory information needed to interpret the results shown (in tables, this is 
frequently done as footnotes)  
o culture parameters or conditions if applicable (temperature, media, etc.) 
o sample sizes and statistical test summaries, as they apply 
Do not simply restate the axis labels with a ‘versus’ written in between.  
Example:  Figure 1: Height frequency (%) of White Pines (Pinusstrobus) in the Thorncrag 
Bird Sanctuary, Lewiston, Maine, before and after the Ice Storm of 1998. Before, n = 137, 
after, n = 133. Four trees fell during the storm and were excluded from the post-storm 
survey.  
 
Note: Questions frequently arise about how much methodology to include in the legend, and 
how much results reporting should be done. For laboratory reports, specific results should be 
reported in the results text with a reference to the applicable table or figure. Other than 
culture conditions, methods are similarly confined to the Methods section. 
Footnotes to tables, figures and photographs 
Do not introduce footnotes in the body of the article. Footnotes should be used as follows: 
• Copyright and permissions to reproduce should be clearly stated. 
• Notes about the table as a whole can be left unlinked (i.e. no linking letters or numbers or 
symbols) or linked to, for example, a relevant column heading.  
• Notes about specific parts of the table should be linked using superscript lower case letters 
(preferred), superscript numbers or symbols.  
• If lower case letters are used, it could be confused with the table data; use symbols or 
numbers instead.  
• Do not make use of superscript numbers in parentheses (brackets).  
• If an abbreviation is mentioned for the first time in a table (e.g. ‘CE’ in Table 1), it must be 
defined in a footnote to that table,  (e.g. HE, Heat event (introduced at weekly intervals). 
• Asterisk footnotes are reserved for probability values in tables and usually signify the 
following values: *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001. The asterisk is often used in 
mathematics and should therefore be avoided as a footnote symbol. 
• Footnote links should be placed after punctuation. The preferred order of footnote symbols in 
tables (which should be superscripted) is  †, ‡, §, ¶ (these are doubled if more footnotes are 
needed, e.g. ††).  
• When superscript numbers or letters are used in text, beware of potential confusion with other 
superscripts (e.g. 2 for ‘squared’).  
• Footnotes should be in the following order:   
o source notes  
o other general notes  
o notes on specific parts of the table (following the order in the table itself)  
o notes on level of probability  
Guidance on submitting creatives electronically 
Supply your manuscript creatives  in one of the following three preferred formats: 
• TIFF: This is an image made up of pixels and is the most universal and most widely 
supported format across Windows and Mac platforms. Most graphics packages can save a file 
as a TIFF. The higher the resolution (i.e. the number of pixels) the sharper the final image.    
o Colour or greyscale photographic images: 300dpi 
o Line art or combination images: 600/900dpi 
o We would recommend using this format for photographic images. 
• EPS: An EPS is essentially an envelope for holding text and images. Line art can be 
produced as an EPS (in Illustrator, for example). There are virtually no limits to scaling line 
art saved as an EPS. It can also contain TIFF images. However, please ensure that all fonts 
are embedded (that is, saved as outlines) and that line weights are not defined as hairline. 
• PDF: This format is, again, like an EPS in that it is an envelope for holding different kinds of 
images and line art. Great care should be taken to ensure that fonts are embedded and that 
original images are at the correct size and resolution before being saved as a PDF. It is 
possible to save or export as TIFF or EPS from most graphics applications, just as it is 
possible to save direct to a PDF from most graphics packages by using a postscript printer 
driver. PDF creation packages (e.g. Acrobat Distiller) are also now widely available. 
Other file formats 
• JPEG: A JPEG compressed TIFF is acceptable as long as the degree of compression is 
moderate. It is better to use a JPEG for online images as a good quality image is achievable 
even with a high degree of compression. 
• GIF: A format suitable for images that contain few colours. Again, this should only be used 
for images intended for the web. 
• We cannot guarantee the quality of images supplied in other formats. 
Colour: 
• Greyscale, CMYK, RGB. 
• Greyscale art should be saved in greyscale mode. 
• CyanMagentaYellowBlack are the base colours used during the printing process. 
• Any colour that is to appear in print must be in CMYK mode. 
• RedGreenBlue are the colours used by monitors and default scanner settings. Any colour that 
is to appear online must be in RGB mode. 
Guidelines for Math ↑ 
• Set display equations in MathType. Each display equation should be in its own MathType 
object. Each MathType object should contain the entire equation, including final punctuation. 
The equation number should be set as Microsoft Word regular text, outside the MathType 
object, separated by either a tab or a space. 
• Set in-text (inline) math in Microsoft Word regular text. Exception: If in-text (inline) math 
has elements that should be stacked or have rules, circumflexes, arrows, or other accents 
spanning over more than one character, set in MathType as ‘Inline Equation.’ 
• If any characters cannot be found in Word’s Symbol palette (‘(normal text),’  ‘Times New 
Roman,’ or ‘Symbol’), please set in MathType. 
• No display equations are allowed in figure captions, table titles, or table footnotes. If a 
display equation occurs in a text footnote, it is best to recast it as inline math. There are a few 
journals with lengthy footnotes with style exceptions to this rule. 
• No numbered equations are allowed in table footnotes. 
• Display and/or numbered equations ARE allowed in table body, but must be ‘inline’ when 
converted to MathML equations. 
 
Structure and style of your original research article 
The page provides an overview of the structure and style of your original research article to 
be submitted to the African Vision and Eye Health. An original article provides an overview 
of innovative research in a particular field within or related to the focus and scope of the 
journal, presented according to a clear and well-structured format (between 3500 and 7000 
words with a maximum of 60 references). 
 
When presenting your article in English. Please use British English, that is, according to the 
Oxford English Dictionary. Avoid Americanisms (e.g. use ‘s’ and not ‘z’ spellings). Consult 
the Oxford English Dictionary when in doubt and remember to set your version of Microsoft 
Word to UK English. 
 
Language: Manuscripts must be written in British English or French. 
Line numbers: Insert continuous line numbers. 
Font type: Palatino  
Symbols font type: Times New Roman  
General font size: 12pt  
Line spacing: 1.5 
Headings: Ensure that formatting for headings is consistent in the manuscript. 
First headings: normal case, bold and 14pt 
Second headings: normal case, underlined and 14pt 
Third headings: normal case, bold and 12pt 
Fourth headings: normal case, bold, running-in text and separated by a colon. 
Our publication system supports a limited range of formats for text and graphics. Text files 
can be submitted in the following formats only: 
 
Microsoft Word (.doc): We cannot accept Word 2007 DOCX files. If you have created your 
manuscript using Word 2007, you must save the document as a Word 2003 file before 
submission. 
Rich Text Format (RTF) documents uploaded during Step 2 of the submission process. Users 
of other word processing packages should save or convert their files to RTF before 
uploading. Many free tools are available that will make this process easier. 
 For full details on how to ensure your manuscript adheres to the house style, click here. 
 
The structure and style of your original article 
Page 1 
The format of the compulsory cover letter forms part of your submission, is on the first page 
of your manuscript and should always be presented in English. You should provide all of the 
following elements: 
 
Full author details: Provide title(s), full name(s), position(s), affiliation(s) and contact details 
(postal address, email, telephone and cellular number) of each author.  
Corresponding author: Identify to whom all correspondence should be addressed. 
Summary: Lastly, a list containing the number of words, pages, tables, figures and/or other 
supplementary material should accompany the submission. 
Page 2 and onwards 
Title: The article’s full title should contain a maximum of 95 characters (including spaces). 
 
Abstract: The abstract, written in English, should be no longer than 250 words and must be 
written in the past tense. The abstract should give a succinct account of the objectives, 
methods, results and significance of the matter. The structured abstract for an Original 
Research article should consist of six paragraphs labelled Background, Aim, Setting, 
Methods, Results and Conclusion. The journal can translate into French if this is difficult for 
you. 
 
Background: Summarise the social value (importance, relevance) and scientific value 
(knowledge gap) that your study addresses. 
Aim: State the overall aim of the study. 
Setting: State the setting for the study. 
Methods: Clearly express the basic design of the study, and name or briefly describe the 
methods used without going into excessive detail. 
Results: State the main findings. 
Conclusion: State your conclusion and any key implications or recommendations. 
Do not cite references and do not use abbreviations excessively in the abstract. 
 
The following headings serve as a guide for presenting your research in a well-structured 
original article. As an author you should include all first-level headings, but subsequent 
headings (second- and third-level headings) can be changed. 
 
Introduction (first-level heading) 
The introduction must contain your argument for the social and scientific value of the study, 
as well as the aim and objectives: 
 
Social value: The first part of the introduction should make a clear and logical argument for 
the importance or relevance of the study. Your argument should be supported by use of 
evidence from the literature. 
 
Scientific value: The second part of the introduction should make a clear and logical 
argument for the originality of the study. This should include a summary of what is already 
known about the research question or specific topic, and should clarify the knowledge gap 
that this study will address. Your argument should be supported by use of evidence from the 
literature. 
 
Conceptual framework: In some research articles it will also be important to describe the 
underlying theoretical basis for the research and how these theories are linked together in a 
conceptual framework. The theoretical evidence used to construct the conceptual framework 
should be referenced from the literature.  
 
Aim and objectives: The introduction should conclude with a clear summary of the aim and 
objectives of this study. 
 
Research methods and design (first-level heading) 
The methods should include: 
 
Study design (second-level heading): An outline of the type of study design. 
 
Setting (second-level heading): A description of the setting for the study; for example, the 
type of community from which the participants came or the nature of the health system and 
services in which the study is conducted. 
 
Study population and sampling strategy (second-level heading): Describe the study 
population and any inclusion or exclusion criteria. Describe the intended sample size and 
your sample size calculation or justification. Describe the sampling strategy used. Describe in 
practical terms how this was implemented. 
 
Intervention (if appropriate) (second-level heading): If there were intervention and 
comparison groups, describe the intervention in detail and what happened to the comparison 
groups.  
 
Data collection (second-level heading): Define the data collection tools that were used and 
their validity. Describe in practical terms how data were collected and any key issues 
involved, e.g. language barriers. 
 
Data analysis (second-level heading): Describe how data were captured, checked and 
cleaned. Describe the analysis process, for example, the statistical tests used orsteps followed 
in qualitative data analysis. 
 
Ethical considerations (second-level heading): Approval must have been obtained for all 
studies from the author's institution or other relevant ethics committee and the institution’s 
name and permit numbers should be stated here. 
 
Results (first-level heading) 
Present the results of your study in a logical sequence that addresses the aim and objectives of 
your study. Use tables and figures as required to present your findings. Use quotations as 
required to establish your interpretation of qualitative data. 
 
All units should conform to the SI convention and be abbreviated accordingly. Metric units 
and their international symbols are used throughout, as is the decimal point (not the decimal 
comma). 
 
Discussion (first-level heading) 
The discussion section should address the following four elements: 
 
Key findings: Summarise the key findings without reiterating details of the results. 
 
Discussion of key findings: Explain how the key findings relate to previous research or to 
existing knowledge, practice or policy. 
 
Strengths and limitations: Describe the strengths and limitations of your methods and what 
the reader should take into account when interpreting your results. 
 
Implications or recommendations: State the implications of your study or recommendations 
for future research (questions that remain unanswered), policy or practice. Make sure that the 
recommendations flow directly from your findings. 
 
Conclusion (first-level heading)  
Provide a brief conclusion that summarises the results and their meaning or significance in 
relation to each objective of the study. 
 
Acknowledgements (first-level heading)  
If, through your study, you received any significant help in conceiving, designing or carrying 
out the work, or received materials from someone who did you a favour by supplying them, 
you must acknowledge their assistance and the service or material provided. Authors should 
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  FILE='E:\2016_MFK\Konsultasie\Ander\EttienneLeRoux20161121.sav'. 
 
Warning # 5281.  Command name: GET FILE 
SPSS Statistics is running in Unicode encoding mode.  This file is encoded in 
a locale-specific (code page) encoding.  The defined width of any string 
variables are automatically tripled in order to avoid possible data loss.  You 
can use ALTER TYPE to set the width of string variables to the width of the 
longest observed value for each string variable. 
















Split File <none> 
Syntax ALTER TYPE ALL(A=AMIN). 
Resources Processor Time 00:00:00.00 








PatientNo A6 AMIN 
SEX A3 AMIN 
RACE A3 AMIN 
OD_OS A6 AMIN 
Year1_1 A3 AMIN 
Year1_5 A6 AMIN 
 
DATASET NAME DataSet1 WINDOW=FRONT. 
FREQUENCIES VARIABLES=FollowUp 








AGE CODE 1=Younger than 70 
2=Between 70 and 74 
3=Between 75 and 79 
4=Between 80 and 84 








Active Dataset DataSet1 
Filter <none> 
Weight <none> 
Split File <none> 
N of Rows in Working Data 
File 
53 
Missing Value Handling Definition of Missing User-defined missing values are 
treated as missing. 




  /ORDER=ANALYSIS. 
Resources Processor Time 00:00:00.00 








FollowUp   





 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid 1.0 29 54.7 54.7 54.7 
2.0 24 45.3 45.3 100.0 
Total 53 100.0 100.0  
 
FREQUENCIES VARIABLES=AGE Age_code SEX gender_Code RACE Race_code OD_OS OD_OS_Code 














Active Dataset DataSet1 
Filter <none> 
Weight <none> 
Split File <none> 
N of Rows in Working Data 
File 
53 
Missing Value Handling Definition of Missing User-defined missing values are 
treated as missing. 
Cases Used Statistics are based on all cases with 
valid data. 
Syntax FREQUENCIES VARIABLES=AGE 
Age_code SEX gender_Code RACE 
Race_code OD_OS OD_OS_Code 
  /ORDER=ANALYSIS. 
Resources Processor Time 00:00:00.00 












N Valid 53 53 53 53 53 53   
Missin
g 




 OD_OS OD_OS_Code 
N Valid 53 53 









 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid 61 1 1.9 1.9 1.9 
62 1 1.9 1.9 3.8 
68 2 3.8 3.8 7.5 
71 2 3.8 3.8 11.3 
72 3 5.7 5.7 17.0 
73 3 5.7 5.7 22.6 
74 1 1.9 1.9 24.5 
75 5 9.4 9.4 34.0 
76 3 5.7 5.7 39.6 
77 2 3.8 3.8 43.4 
79 3 5.7 5.7 49.1 
80 3 5.7 5.7 54.7 
81 2 3.8 3.8 58.5 
82 2 3.8 3.8 62.3 
83 5 9.4 9.4 71.7 
84 4 7.5 7.5 79.2 
86 7 13.2 13.2 92.5 
89 1 1.9 1.9 94.3 
90 1 1.9 1.9 96.2 
93 2 3.8 3.8 100.0 




 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid 1.0 4 7.5 7.5 7.5 
2.0 9 17.0 17.0 24.5 
3.0 13 24.5 24.5 49.1 
4.0 16 30.2 30.2 79.2 
5.0 11 20.8 20.8 100.0 




 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid F 24 45.3 45.3 45.3 
M 29 54.7 54.7 100.0 
Total 53 100.0 100.0  
 
Gender Code : 
1 = Female  





 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid 1.0 24 45.3 45.3 45.3 
2.0 29 54.7 54.7 100.0 




 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid B 3 5.7 5.7 5.7 
I 8 15.1 15.1 20.8 
W 42 79.2 79.2 100.0 
Total 53 100.0 100.0  
 
Race Code: 
1 = Black 
2 = Indian 




 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid 1 3 5.7 5.7 5.7 
2 8 15.1 15.1 20.8 
3 42 79.2 79.2 100.0 
Total 53 100.0 100.0  
 
OD_OS 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid OD 31 58.5 58.5 58.5 
OS 22 41.5 41.5 100.0 




2 = OS 
 
OD_OS_Code 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid 1.0 31 58.5 58.5 58.5 
2.0 22 41.5 41.5 100.0 
Total 53 100.0 100.0  
 
DESCRIPTIVES VARIABLES=VA_Start VA_1year VA_2year 











Active Dataset DataSet1 
Filter <none> 
Weight <none> 
Split File <none> 
N of Rows in Working Data 
File 
53 
Missing Value Handling Definition of Missing User defined missing values are treated 
as missing. 




  /STATISTICS=MEAN STDDEV MIN 
MAX KURTOSIS SKEWNESS. 
Resources Processor Time 00:00:00.00 

















VA_Start 53 .0 .8 .213 .1743 1.637 .327   
VA_1year 53 .1 1.0 .383 .2673 .846 .327   
VA_2year 24 .10 1.00 .4479 .26600 .519 .472   
Valid N 
(listwise) 






Statistic Std. Error 
VA_Start 3.229 .644 
VA_1year -.083 .644 
VA_2year -1.011 .918 
Valid N (listwise)   
 
DESCRIPTIVES VARIABLES=CMT_Start CMT_1year CMT_2year 














Active Dataset DataSet1 
Filter <none> 
Weight <none> 
Split File <none> 
N of Rows in Working Data 
File 
53 
Missing Value Handling Definition of Missing User defined missing values are treated 
as missing. 




  /STATISTICS=MEAN STDDEV MIN 
MAX KURTOSIS SKEWNESS. 
Resources Processor Time 00:00:00.02 

















CMT_Start 48 215.0 611.0 333.458 85.4430 1.160 .343   
CMT_1year 48 134.0 774.0 265.354 93.5554 3.528 .343   
CMT_2year 24 172.0 349.0 245.792 49.7734 .494 .472   
Valid N 
(listwise) 






Statistic Std. Error 
CMT_Start 1.470 .674 
CMT_1year 18.316 .674 
CMT_2year -.358 .918 
Valid N (listwise)   
 


















Active Dataset DataSet1 
Filter <none> 
Weight <none> 
Split File <none> 
N of Rows in Working Data 
File 
53 
Missing Value Handling Definition of Missing User defined missing values are treated 
as missing. 
Cases Used All non-missing data are used. 
Syntax DESCRIPTIVES 
VARIABLES=BetweenTime_1 
  /STATISTICS=MEAN STDDEV MIN 
MAX KURTOSIS SKEWNESS. 
Resources Processor Time 00:00:00.00 





N Minimum Maximum Mean 
Std. 
Deviation 
    
Statisti
c Statistic Statistic Statistic Statistic 














    
Valid N 
(listwise) 
53     





Statistic Std. Error Statistic Std. Error 
BetweenTime_1 1.202 .327 1.766 .644 
Valid N (listwise)     
 


















Active Dataset DataSet1 
Filter <none> 
Weight <none> 
Split File <none> 
N of Rows in Working Data 
File 
53 
Missing Value Handling Definition of Missing User defined missing values are treated 
as missing. 
Cases Used All non-missing data are used. 
Syntax DESCRIPTIVES 
VARIABLES=BetweenTime_2 
  /STATISTICS=MEAN STDDEV MIN 
MAX KURTOSIS SKEWNESS. 
Resources Processor Time 00:00:00.00 





N Minimum Maximum Mean 
Std. 
Deviation 
    
Statisti
c Statistic Statistic Statistic Statistic 













    
Valid N 
(listwise) 
25     





Statistic Std. Error Statistic Std. Error 
BetweenTime_2 .312 .464 -1.166 .902 
Valid N (listwise)     
 




    Year1_10,Year1_11,Year1_12,Year2_1,Year2_2,Year2_3,Year2_4,Year2_5,Year2_6,Year2_7,Year2_8,Year2_9, 
    Year2_10). 
EXECUTE. 
DESCRIPTIVES VARIABLES=TimeBetweenInj 














Active Dataset DataSet1 
Filter <none> 
Weight <none> 
Split File <none> 
N of Rows in Working Data 
File 
53 
Missing Value Handling Definition of Missing User defined missing values are treated 
as missing. 
Cases Used All non-missing data are used. 
Syntax DESCRIPTIVES 
VARIABLES=TimeBetweenInj 
  /STATISTICS=MEAN STDDEV MIN 
MAX KURTOSIS SKEWNESS. 
Resources Processor Time 00:00:00.02 





























Statistic Std. Error 
TimeBetweenInj .409 .644 
Valid N (listwise)   
 
FREQUENCIES VARIABLES=Year1_1 Year1_2 Year1_3 Year1_4 Year1_5 Year1_6 Year1_7 Year1_8 Year1_9 
    Year1_10 Year1_11 Year1_12 Year2_1 Year2_2 Year2_3 Year2_4 Year2_5 Year2_6 Year2_7 Year2_8 Year2_9 
    Year2_10 
  /STATISTICS=STDDEV MINIMUM MAXIMUM MEAN MEDIAN SKEWNESS SESKEW KURTOSIS SEKURT 














Active Dataset DataSet1 
Filter <none> 
Weight <none> 
Split File <none> 
N of Rows in Working Data 
File 
53 
Missing Value Handling Definition of Missing User-defined missing values are 
treated as missing. 
Cases Used Statistics are based on all cases with 
valid data. 
Syntax FREQUENCIES VARIABLES=Year1_1 
Year1_2 Year1_3 Year1_4 Year1_5 
Year1_6 Year1_7 Year1_8 Year1_9 
    Year1_10 Year1_11 Year1_12 
Year2_1 Year2_2 Year2_3 Year2_4 
Year2_5 Year2_6 Year2_7 Year2_8 
Year2_9 
    Year2_10 
  /STATISTICS=STDDEV MINIMUM 
MAXIMUM MEAN MEDIAN 
SKEWNESS SESKEW KURTOSIS 
SEKURT 
  /ORDER=ANALYSIS. 
Resources Processor Time 00:00:00.00 
Elapsed Time 00:00:00.03 
 
 
 Year1_1 Year1_2 Year1_3 Year1_4 Year1_5 Year1_6 Year1_7 
N Valid 53 53 53 52 51 49 45 
Missing 0 0 0 1 2 4 8 
Mean 4.302 4.113 4.962 5.885 5.863 6.490 6.289 
Median 4.000 4.000 4.000 4.000 6.000 6.000 6.000 
Std. Deviation 1.0112 .5771 2.1390 4.1000 2.1356 2.3728 2.3122 
Skewness 4.105 3.123 3.322 3.764 1.250 .857 .531 
Std. Error of 
Skewness 
.327 .327 .327 .330 .333 .340 .354 
Kurtosis 17.133 13.754 13.683 15.233 1.114 .358 -.881 
Std. Error of 
Kurtosis 
.644 .644 .644 .650 .656 .668 .695 
Minimum 4.0 3.0 3.0 4.0 4.0 4.0 4.0 
Maximum 9.0 7.0 16.0 26.0 12.0 13.0 12.0 
 
 Year1_8 Year1_9 Year1_10 Year1_11 Year1_12 Year2_1 
N Valid 39 28 19 12 4 24 
Missing 14 25 34 41 49 29 
Mean 6.000 4.929 5.526 4.667 4.250 8.542 
Median 5.000 4.000 4.000 4.000 4.000 8.000 
Std. Deviation 2.4170 1.1841 2.0915 .9847 .5000 2.7184 
Skewness 1.155 1.012 1.282 .812 2.000 .064 
Std. Error of 
Skewness 
.378 .441 .524 .637 1.014 .472 
Kurtosis .307 .045 .896 -1.650 4.000 -.609 
Std. Error of 
Kurtosis 
.741 .858 1.014 1.232 2.619 .918 
Minimum 4.0 4.0 4.0 4.0 4.0 4.0 
Maximum 12.0 8.0 11.0 6.0 5.0 14.0 
 
 Year2_2 Year2_3 Year2_4 Year2_5 Year2_6 Year2_7 Year2_8 
N Valid 23 22 19 16 11 11 9 
Missing 30 31 34 37 42 42 44 
Mean 7.826 9.182 7.895 8.250 6.182 5.909 4.778 
Median 7.000 9.500 7.000 8.000 6.000 5.000 4.000 
Std. Deviation 3.4726 3.5675 3.9426 3.3367 1.8878 2.1659 1.2019 
Skewness .374 .092 .677 .083 .663 .503 1.093 
Std. Error of 
Skewness 
.481 .491 .524 .564 .661 .661 .717 
Kurtosis -1.217 -1.076 -.836 -1.679 .199 -1.768 -.586 
Std. Error of 
Kurtosis 
.935 .953 1.014 1.091 1.279 1.279 1.400 
Minimum 4.0 4.0 4.0 4.0 4.0 4.0 4.0 
Maximum 14.0 16.0 16.0 13.0 10.0 9.0 7.0 
 
Statistics 
 Year2_9 Year2_10 
N Valid 7 3 
Missing 46 50 
Mean 5.571 4.667 
Median 6.000 4.000 
Std. Deviation 1.6183 1.1547 
Skewness .317 1.732 
Std. Error of Skewness .794 1.225 
Kurtosis -1.501  
Std. Error of Kurtosis 1.587  
Minimum 4.0 4.0 







 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid 4.0 46 86.8 86.8 86.8 
5.0 4 7.5 7.5 94.3 
6.0 1 1.9 1.9 96.2 
9.0 2 3.8 3.8 100.0 
Total 53 100.0 100.0  
 
Year1_2 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid 3.0 2 3.8 3.8 3.8 
4.0 46 86.8 86.8 90.6 
5.0 3 5.7 5.7 96.2 
6.0 1 1.9 1.9 98.1 
7.0 1 1.9 1.9 100.0 
Total 53 100.0 100.0  
Year1_3 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid 3.0 1 1.9 1.9 1.9 
4.0 36 67.9 67.9 69.8 
5.0 2 3.8 3.8 73.6 
6.0 9 17.0 17.0 90.6 
8.0 2 3.8 3.8 94.3 
10.0 2 3.8 3.8 98.1 
16.0 1 1.9 1.9 100.0 
Total 53 100.0 100.0  
 
Year1_4 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid 4.0 27 50.9 51.9 51.9 
5.0 8 15.1 15.4 67.3 
6.0 7 13.2 13.5 80.8 
7.0 2 3.8 3.8 84.6 
8.0 5 9.4 9.6 94.2 
14.0 1 1.9 1.9 96.2 
22.0 1 1.9 1.9 98.1 
26.0 1 1.9 1.9 100.0 
Total 52 98.1 100.0  
Missing System 1 1.9   
Total 53 100.0   
 
Year1_5 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid 4.0 20 37.7 39.2 39.2 
5.0 5 9.4 9.8 49.0 
6.0 13 24.5 25.5 74.5 
7.0 2 3.8 3.9 78.4 
8.0 5 9.4 9.8 88.2 
9.0 2 3.8 3.9 92.2 
10.0 2 3.8 3.9 96.1 
12.0 2 3.8 3.9 100.0 
Total 51 96.2 100.0  
Missing System 2 3.8   
Total 53 100.0   
Year1_6 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid 4.0 16 30.2 32.7 32.7 
5.0 1 1.9 2.0 34.7 
6.0 11 20.8 22.4 57.1 
7.0 4 7.5 8.2 65.3 
8.0 11 20.8 22.4 87.8 
10.0 3 5.7 6.1 93.9 
12.0 2 3.8 4.1 98.0 
13.0 1 1.9 2.0 100.0 
Total 49 92.5 100.0  
Missing System 4 7.5   
Total 53 100.0   
 
Year1_7 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid 4.0 18 34.0 40.0 40.0 
5.0 2 3.8 4.4 44.4 
6.0 6 11.3 13.3 57.8 
7.0 2 3.8 4.4 62.2 
8.0 9 17.0 20.0 82.2 
9.0 3 5.7 6.7 88.9 
10.0 4 7.5 8.9 97.8 
12.0 1 1.9 2.2 100.0 
Total 45 84.9 100.0  
Missing System 8 15.1   





 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid 4.0 16 30.2 41.0 41.0 
5.0 5 9.4 12.8 53.8 
6.0 7 13.2 17.9 71.8 
7.0 1 1.9 2.6 74.4 
8.0 4 7.5 10.3 84.6 
10.0 4 7.5 10.3 94.9 
12.0 2 3.8 5.1 100.0 
Total 39 73.6 100.0  
Missing System 14 26.4   
Total 53 100.0   
Year1_9 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid 4.0 15 28.3 53.6 53.6 
5.0 4 7.5 14.3 67.9 
6.0 6 11.3 21.4 89.3 
7.0 2 3.8 7.1 96.4 
8.0 1 1.9 3.6 100.0 
Total 28 52.8 100.0  
Missing System 25 47.2   
Total 53 100.0   
 
Year1_10 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid 4.0 10 18.9 52.6 52.6 
5.0 2 3.8 10.5 63.2 
6.0 2 3.8 10.5 73.7 
8.0 4 7.5 21.1 94.7 
11.0 1 1.9 5.3 100.0 
Total 19 35.8 100.0  
Missing System 34 64.2   
Total 53 100.0   
 
Year1_11 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid 4.0 8 15.1 66.7 66.7 
6.0 4 7.5 33.3 100.0 
Total 12 22.6 100.0  
Missing System 41 77.4   





 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid 4.0 3 5.7 75.0 75.0 
5.0 1 1.9 25.0 100.0 
Total 4 7.5 100.0  
Missing System 49 92.5   
Total 53 100.0   
 
Year2_1 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid 4.0 2 3.8 8.3 8.3 
5.0 2 3.8 8.3 16.7 
6.0 2 3.8 8.3 25.0 
7.0 1 1.9 4.2 29.2 
8.0 6 11.3 25.0 54.2 
9.0 2 3.8 8.3 62.5 
10.0 4 7.5 16.7 79.2 
12.0 4 7.5 16.7 95.8 
14.0 1 1.9 4.2 100.0 
Total 24 45.3 100.0  
Missing System 29 54.7   
Total 53 100.0   
 
Year2_2 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid 4.0 7 13.2 30.4 30.4 
6.0 4 7.5 17.4 47.8 
7.0 1 1.9 4.3 52.2 
8.0 1 1.9 4.3 56.5 
9.0 1 1.9 4.3 60.9 
10.0 4 7.5 17.4 78.3 
12.0 3 5.7 13.0 91.3 
14.0 2 3.8 8.7 100.0 
Total 23 43.4 100.0  
Missing System 30 56.6   
Total 53 100.0   
Year2_3 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid 4.0 3 5.7 13.6 13.6 
6.0 4 7.5 18.2 31.8 
7.0 2 3.8 9.1 40.9 
8.0 1 1.9 4.5 45.5 
9.0 1 1.9 4.5 50.0 
10.0 1 1.9 4.5 54.5 
11.0 3 5.7 13.6 68.2 
12.0 4 7.5 18.2 86.4 
14.0 2 3.8 9.1 95.5 
16.0 1 1.9 4.5 100.0 
Total 22 41.5 100.0  
Missing System 31 58.5   
Total 53 100.0   
 
Year2_4 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid 4.0 6 11.3 31.6 31.6 
5.0 1 1.9 5.3 36.8 
6.0 2 3.8 10.5 47.4 
7.0 1 1.9 5.3 52.6 
8.0 3 5.7 15.8 68.4 
11.0 1 1.9 5.3 73.7 
12.0 2 3.8 10.5 84.2 
13.0 1 1.9 5.3 89.5 
14.0 1 1.9 5.3 94.7 
16.0 1 1.9 5.3 100.0 
Total 19 35.8 100.0  
Missing System 34 64.2   





 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid 4.0 3 5.7 18.8 18.8 
5.0 1 1.9 6.3 25.0 
6.0 3 5.7 18.8 43.8 
8.0 2 3.8 12.5 56.3 
9.0 1 1.9 6.3 62.5 
11.0 1 1.9 6.3 68.8 
12.0 4 7.5 25.0 93.8 
13.0 1 1.9 6.3 100.0 
Total 16 30.2 100.0  
Missing System 37 69.8   
Total 53 100.0   
Year2_6 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid 4.0 3 5.7 27.3 27.3 
6.0 5 9.4 45.5 72.7 
8.0 2 3.8 18.2 90.9 
10.0 1 1.9 9.1 100.0 
Total 11 20.8 100.0  
Missing System 42 79.2   




 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid 4.0 5 9.4 45.5 45.5 
5.0 1 1.9 9.1 54.5 
6.0 1 1.9 9.1 63.6 
8.0 2 3.8 18.2 81.8 
9.0 2 3.8 18.2 100.0 
Total 11 20.8 100.0  
Missing System 42 79.2   




 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid 4.0 6 11.3 66.7 66.7 
6.0 2 3.8 22.2 88.9 
7.0 1 1.9 11.1 100.0 
Total 9 17.0 100.0  
Missing System 44 83.0   





 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid 4.0 3 5.7 42.9 42.9 
6.0 2 3.8 28.6 71.4 
7.0 1 1.9 14.3 85.7 
8.0 1 1.9 14.3 100.0 
Total 7 13.2 100.0  
Missing System 46 86.8   
Total 53 100.0   
 
Year2_10 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid 4.0 2 3.8 66.7 66.7 
6.0 1 1.9 33.3 100.0 
Total 3 5.7 100.0  
Missing System 50 94.3   
Total 53 100.0   
 
T-TEST PAIRS=VA_Start VA_Start VA_1year WITH VA_1year VA_2year VA_2year (PAIRED) 
  /CRITERIA=CI(.9500) 











Active Dataset DataSet1 
Filter <none> 
Weight <none> 
Split File <none> 
N of Rows in Working Data 
File 
53 
Missing Value Handling Definition of Missing User defined missing values are treated 
as missing. 
Cases Used Statistics for each analysis are based 
on the cases with no missing or 
out-of-range data for any variable in the 
analysis. 
Syntax T-TEST PAIRS=VA_Start VA_Start 
VA_1year WITH VA_1year VA_2year 
VA_2year (PAIRED) 
  /CRITERIA=CI(.9500) 
  /MISSING=ANALYSIS. 
Resources Processor Time 00:00:00.00 
Elapsed Time 00:00:00.03 
 
 
Paired Samples Statistics 
 Mean N Std. Deviation Std. Error Mean 
Pair 1 VA_Start .213 53 .1743 .0239 
VA_1year .383 53 .2673 .0367 
Pair 2 VA_Start .269 24 .2100 .0429 
VA_2year .4479 24 .26600 .05430 
Pair 3 VA_1year .442 24 .2773 .0566 
VA_2year .4479 24 .26600 .05430 
 
 
Paired Samples Correlations 
 N Correlation Sig. 
Pair 1 VA_Start & VA_1year 53 .310 .024 
Pair 2 VA_Start & VA_2year 24 .114 .597 





Mean Std. Deviation Std. Error Mean 
95% Confidence 





VA_Start - VA_1year 
-.1704 .2701 .0371 -.2448 
Pair 
2 
VA_Start - VA_2year 
-.17917 .31962 .06524 -.31413 
Pair 
3 
VA_1year - VA_2year 
-.00625 .25251 .05154 -.11288 
 
Paired Samples Test 
 
Paired Differences 
t df Sig. (2-tailed) 
95% Confidence 
Interval of the 
Difference 
Upper 
Pair 1 VA_Start - VA_1year -.0959 -4.592 52 .000 
Pair 2 VA_Start - VA_2year -.04420 -2.746 23 .012 
Pair 3 VA_1year - VA_2year .10038 -.121 23 .905 
 
T-TEST PAIRS=CMT_Start CMT_Start CMT_1year WITH CMT_1year CMT_2year CMT_2year (PAIRED) 
  /CRITERIA=CI(.9500) 














Active Dataset DataSet1 
Filter <none> 
Weight <none> 
Split File <none> 
N of Rows in Working Data 
File 
53 
Missing Value Handling Definition of Missing User defined missing values are treated 
as missing. 
Cases Used Statistics for each analysis are based 
on the cases with no missing or 
out-of-range data for any variable in the 
analysis. 
Syntax T-TEST PAIRS=CMT_Start CMT_Start 
CMT_1year WITH CMT_1year 
CMT_2year CMT_2year (PAIRED) 
  /CRITERIA=CI(.9500) 
  /MISSING=ANALYSIS. 
Resources Processor Time 00:00:00.00 
Elapsed Time 00:00:00.01 
 
 
Paired Samples Statistics 
 Mean N Std. Deviation Std. Error Mean 
Pair 1 CMT_Start 333.458 48 85.4430 12.3326 
CMT_1year 265.354 48 93.5554 13.5036 
Pair 2 CMT_Start 325.458 24 79.0305 16.1320 
CMT_2year 245.792 24 49.7734 10.1599 
Pair 3 CMT_1year 251.667 24 51.7961 10.5728 
CMT_2year 245.792 24 49.7734 10.1599 
 
 
Paired Samples Correlations 
 N Correlation Sig. 
Pair 1 CMT_Start & CMT_1year 48 .485 .000 
Pair 2 CMT_Start & CMT_2year 24 .521 .009 




 Paired Differences 
 Mean Std. Deviation Std. Error Mean 
95% Confidence Interval 
of the Difference 
Lower 
Pair 1 CMT_Start - CMT_1year 68.1042 91.1273 13.1531 41.6436 
Pair 2 CMT_Start - CMT_2year 79.6667 67.9851 13.8774 50.9591 
Pair 3 CMT_1year - CMT_2year 5.8750 23.0977 4.7148 -3.8783 
 
Paired Samples Test 
 
Paired Differences 
t df Sig. (2-tailed) 
95% Confidence 
Interval of the 
Difference 
Upper 
Pair 1 CMT_Start - CMT_1year 94.5648 5.178 47 .000 
Pair 2 CMT_Start - CMT_2year 108.3742 5.741 23 .000 
Pair 3 CMT_1year - CMT_2year 15.6283 1.246 23 .225 
 
CORRELATIONS 
  /VARIABLES=VA_Start VA_1year VA_2year BetweenTime_1 BetweenTime_2 
  /PRINT=TWOTAIL NOSIG 














Active Dataset DataSet1 
Filter <none> 
Weight <none> 
Split File <none> 
N of Rows in Working Data 
File 
53 
Missing Value Handling Definition of Missing User-defined missing values are 
treated as missing. 
Cases Used Statistics for each pair of variables are 
based on all the cases with valid data 
for that pair. 
Syntax CORRELATIONS 
  /VARIABLES=VA_Start VA_1year 
VA_2year BetweenTime_1 
BetweenTime_2 
  /PRINT=TWOTAIL NOSIG 
  /MISSING=PAIRWISE. 
Resources Processor Time 00:00:00.00 
Elapsed Time 00:00:00.01 
 
 
 VA_Start VA_1year VA_2year BetweenTime_1 
VA_Start Pearson Correlation 1 .310* .114 .451** 
Sig. (2-tailed)  .024 .597 .001 
N 53 53 24 53 
VA_1year Pearson Correlation .310* 1 .569** .160 
Sig. (2-tailed) .024  .004 .251 
N 53 53 24 53 
VA_2year Pearson Correlation .114 .569** 1 .179 
Sig. (2-tailed) .597 .004  .402 
N 24 24 24 24 
BetweenTime_
1 
Pearson Correlation .451** .160 .179 1 
Sig. (2-tailed) .001 .251 .402  
N 53 53 24 53 
BetweenTime_
2 
Pearson Correlation .392 .230 .168 .660** 
Sig. (2-tailed) .053 .269 .434 .000 




VA_Start Pearson Correlation .392 
Sig. (2-tailed) .053 
N 25 
VA_1year Pearson Correlation .230 
Sig. (2-tailed) .269 
N 25 
VA_2year Pearson Correlation .168 
Sig. (2-tailed) .434 
N 24 
BetweenTime_1 Pearson Correlation .660** 
Sig. (2-tailed) .000 
N 25 
BetweenTime_2 Pearson Correlation 1 
Sig. (2-tailed)  
N 25 
 
*. Correlation is significant at the 0.05 level (2-tailed). 
**. Correlation is significant at the 0.01 level (2-tailed). 
 
CORRELATIONS 
  /VARIABLES=CMT_Start CMT_1year CMT_2year BetweenTime_1 BetweenTime_2 
  /PRINT=TWOTAIL NOSIG 














Active Dataset DataSet1 
Filter <none> 
Weight <none> 
Split File <none> 
N of Rows in Working Data 
File 
53 
Missing Value Handling Definition of Missing User-defined missing values are 
treated as missing. 
Cases Used Statistics for each pair of variables are 
based on all the cases with valid data 
for that pair. 
Syntax CORRELATIONS 
  /VARIABLES=CMT_Start CMT_1year 
CMT_2year BetweenTime_1 
BetweenTime_2 
  /PRINT=TWOTAIL NOSIG 
  /MISSING=PAIRWISE. 
Resources Processor Time 00:00:00.02 
Elapsed Time 00:00:00.04 
 
 
 CMT_Start CMT_1year CMT_2year BetweenTime_1 
CMT_Start Pearson Correlation 1 .485** .521** -.261 
Sig. (2-tailed)  .000 .009 .073 
N 48 48 24 48 
CMT_1year Pearson Correlation .485** 1 .897** -.284 
Sig. (2-tailed) .000  .000 .050 
N 48 48 24 48 
CMT_2year Pearson Correlation .521** .897** 1 -.236 
Sig. (2-tailed) .009 .000  .267 
N 24 24 24 24 
BetweenTime_1 Pearson Correlation -.261 -.284 -.236 1 
Sig. (2-tailed) .073 .050 .267  
N 48 48 24 53 
BetweenTime_2 Pearson Correlation -.425* -.431* -.260 .660** 
Sig. (2-tailed) .034 .031 .221 .000 




CMT_Start Pearson Correlation -.425* 
Sig. (2-tailed) .034 
N 25 
CMT_1year Pearson Correlation -.431* 
Sig. (2-tailed) .031 
N 25 
CMT_2year Pearson Correlation -.260 
Sig. (2-tailed) .221 
N 24 
BetweenTime_1 Pearson Correlation .660** 
Sig. (2-tailed) .000 
N 25 
BetweenTime_2 Pearson Correlation 1 
Sig. (2-tailed)  
N 25 
 
**. Correlation is significant at the 0.01 level (2-tailed). 
*. Correlation is significant at the 0.05 level (2-tailed). 
 
CORRELATIONS 
  /VARIABLES=DVA_Start_year1 DVA_Start_Year2 DVA_Year1_Year2 DCMT_Start_Year1 DCMT_Start_Year2 
    DCMT_Year1_Year2 BetweenTime_1 BetweenTime_2 TimeBetweenInj 
  /PRINT=TWOTAIL NOSIG 














Active Dataset DataSet1 
Filter <none> 
Weight <none> 
Split File <none> 
N of Rows in Working Data 
File 
53 
Missing Value Handling Definition of Missing User-defined missing values are 
treated as missing. 
Cases Used Statistics for each pair of variables are 
based on all the cases with valid data 
for that pair. 
Syntax CORRELATIONS 




    DCMT_Year1_Year2 
BetweenTime_1 BetweenTime_2 
TimeBetweenInj 
  /PRINT=TWOTAIL NOSIG 
  /MISSING=PAIRWISE. 
Resources Processor Time 00:00:00.03 
Elapsed Time 00:00:00.03 
 
 
 Change in VA from Start to Year 1 DVA_Start_Year2 DVA_Year1_Year2 
Change in 
VA from Start 
to Year 1 
Pearson Correlation 1 .700** -.427* 
Sig. (2-tailed)  .000 .037 
N 52 24 24 
DVA_Start_Y
ear2 
Pearson Correlation .700** 1 .346 
Sig. (2-tailed) .000  .097 
N 24 24 24 
DVA_Year1_
Year2 
Pearson Correlation -.427* .346 1 
Sig. (2-tailed) .037 .097  
N 24 24 24 
Change in 
CMT from 
start to Year 
1 
Pearson Correlation -.164 -.191 .077 
Sig. (2-tailed) .269 .372 .721 
N 
47 24 24 
DCMT_Start
_Year2 
Pearson Correlation -.233 -.182 .077 
Sig. (2-tailed) .272 .396 .722 
N 24 24 24 
DCMT_Year
1_Year2 
Pearson Correlation .001 .007 .007 
Sig. (2-tailed) .995 .974 .973 
N 24 24 24 
BetweenTim
e_1 
Pearson Correlation .124 .179 -.152 
Sig. (2-tailed) .381 .403 .479 
N 52 24 24 
BetweenTim
e_2 
Pearson Correlation .056 .100 .030 
Sig. (2-tailed) .789 .642 .890 
N 25 24 24 
TimeBetwee
nInj 
Pearson Correlation .071 .174 .011 
Sig. (2-tailed) .614 .417 .958 
N 52 24 24 
 
 
Change in CMT from start to 
Year 1 DCMT_Start_Year2 DCMT_Year1_Year2 
Change in VA from 
Start to Year 1 
Pearson Correlation -.164 -.233 .001 
Sig. (2-tailed) .269 .272 .995 
N 47 24 24 
DVA_Start_Year2 Pearson Correlation -.191 -.182 .007 
Sig. (2-tailed) .372 .396 .974 
N 24 24 24 
DVA_Year1_Year2 Pearson Correlation .077 .077 .007 
Sig. (2-tailed) .721 .722 .973 
N 24 24 24 
Change in CMT 
from start to Year 1 
Pearson Correlation 1 .941** -.070 
Sig. (2-tailed)  .000 .744 
N 48 24 24 
DCMT_Start_Year2 Pearson Correlation .941** 1 .272 
Sig. (2-tailed) .000  .199 
N 24 24 24 
DCMT_Year1_Year
2 
Pearson Correlation -.070 .272 1 
Sig. (2-tailed) .744 .199  
N 24 24 24 
BetweenTime_1 Pearson Correlation .046 -.125 -.035 
Sig. (2-tailed) .754 .560 .869 
N 48 24 24 
BetweenTime_2 Pearson Correlation -.178 -.208 -.208 
Sig. (2-tailed) .395 .329 .329 
N 25 24 24 
TimeBetweenInj Pearson Correlation .043 -.194 -.168 
Sig. (2-tailed) .770 .365 .432 
N 48 24 24 
 
Correlations 
 BetweenTime_1 BetweenTime_2 TimeBetweenInj 
Change in VA from Start to 
Year 1 
Pearson Correlation .124 .056 .071 
Sig. (2-tailed) .381 .789 .614 
N 52 25 52 
DVA_Start_Year2 Pearson Correlation .179 .100 .174 
Sig. (2-tailed) .403 .642 .417 
N 24 24 24 
DVA_Year1_Year2 Pearson Correlation -.152 .030 .011 
Sig. (2-tailed) .479 .890 .958 
N 24 24 24 
Change in CMT from start to 
Year 1 
Pearson Correlation .046 -.178 .043 
Sig. (2-tailed) .754 .395 .770 
N 48 25 48 
DCMT_Start_Year2 Pearson Correlation -.125 -.208 -.194 
Sig. (2-tailed) .560 .329 .365 
N 24 24 24 
DCMT_Year1_Year2 Pearson Correlation -.035 -.208 -.168 
Sig. (2-tailed) .869 .329 .432 
N 24 24 24 
BetweenTime_1 Pearson Correlation 1 .660** .856** 
Sig. (2-tailed)  .000 .000 
N 53 25 53 
BetweenTime_2 Pearson Correlation .660** 1 .913** 
Sig. (2-tailed) .000  .000 
N 25 25 25 
TimeBetweenInj Pearson Correlation .856** .913** 1 
Sig. (2-tailed) .000 .000  
N 53 25 53 
 
**. Correlation is significant at the 0.01 level (2-tailed). 
*. Correlation is significant at the 0.05 level (2-tailed). 
 
Patient Study Number Follow-up Period AGE SEX RACE OD/OS
1 >1y 80 M I OS
2 >1y 82 F W OD
3 >1y 72 M W OD
4 >1y 80 F W OD
5 >2y 79 M I OD
6 >2y 83 F W OD
7 >1y 89 M W OD
8 >1y 90 M W OS
9 >2y 93 M W OD
10 >1y 72 M W OD
11 >1y 86 M W OS
12 >1y 86 F W OD
13 >1y 82 F I OS
14 >2y 86 F W OD
15 >1y 76 M W OD
16 >2y 84 F I OS
17 >2y 77 M W OS
18 >2y 80 M W OD
19 >1y 86 M W OD
20 >1y 62 M W OD
21 >1y 79 M W OD
22 >1y 83 M W OD
23 >2y 83 M W OS
24 >2y 83 M W OD
25 >2Y 86 M I OD
26 >2Y 86 M I OD
27 >1Y 72 F W OS
28 >2y 84 F W OS
29 >1Y 81 M W OD
30 >1Y 81 M W OS
31 >2y 73 F B OS
32 >1y 61 F W OD
33 >2y 73 M W OS
34 >2y 93 F B OD
35 >2y 75 F W OS
36 >2y 77 F W OS
37 >2y 76 F W OD
38 >2y 73 M W OD
39 >2y 79 M I OD
40 >2y 68 F W OS
41 >2y 83 M W OD
42 >2y 84 F W OD
43 >2y 84 F W OS
44 >1y 76 F W OS
45 >1y 68 M W OS
46 >1y 86 M W OD
47 >1y 75 F W OD
48 >1y 75 F W OS
49 >1y 71 F W OD
50 >1y 75 M W OS
51 >1y 74 M I OD
52 >1y 75 F W OS
53 >1y 71 F B OS
Patient Study Number Exclusion Reason AGE SEX RACE OD/OS
53 eyes of 48 patients3 eyes with 1y follow-up 29 Male 3 African OS-Left-22
24 eyes with 2y follow-up 24 Female 8 IndianOD-Right-31
42 Caucasian
Counting Fingers vision given value of 0   
1.0 is 6/6 vision the closer to 1.0 the bett   
VA Sart CMT Start Date IVI-1 VA 1 year CMT 1 year VA 2 year
0.1 268 11/03/2015 0.15 234
0.1 472 10/07/2013 0.05 774
0.4 215 01/07/2015 0.7 185
0.1 275 22/06/2011 0.15 134
0.3 348 08/06/2011 0.2 299 0.3
0.1 501 15/05/2013 0.2 358 0.2
0.3 258 05/10/2011 0.3 223
0.1 277 27/06/2012 0.1 260
0.3 329 10/08/2011 0.3 216 0.3
0.09 316 12/09/2012 0.1 264
0.3 305 13/05/2015 0.6 257
0.05 335 16/05/2012 0.05 265
0.3 11/01/2012 0.5
0.3 233 21/09/2011 0.5 209 0.3
0.15 346 20/04/2011 0.1 310
0.15 234 16/11/2011 1.0 187 0.4
0.5 297 20/04/2011 0.5 270 0.6
0.2 351 20/04/2011 0.6 247 0.1
0.2 284 22/06/2011 0.2 245
0.3 24/06/2015 0.3
0.3 16/08/2011 0.5
0.15 324 30/01/2013 0.05 207
0.15 379 05/10/2011 0.3 314 0.2
0.1 370 25/01/2012 1.0 177 1.0
0.05 340 27/6/2012 0.15 285 0.6
0.15 457 04/04/2012 0.5 296 0.3
0.01 392 26/11/2014 0.5 266
0.3 225 30/05/2012 0.15 205 0.15
0.2 239 08/08/2012 0.5 233
0.15 611 15/08/2012 0.15 253
0.1 274 03/10/2012 0.15 264 0.1
0.2 373 24/06/2015 0.3 355
0.3 321 21/11/2012 0.8 292 0.8
0.15 232 05/12/2012 0.15 175 0.3
0.15 342 28/11/2012 0.5 327 0.8
0.5 307 30/01/2013 0.4 312 0.4
0.2 294 30/01/2013 0.4 220 0.2
0.5 242 29/05/2013 0.2 233 0.7
0.1 509 17/07/2013 0.3 274 0.4
0.15 298 19/02/2014 0.6 262 0.8
0.1 348 29/01/2014 0.5 187 0.7
0.8 245 27/08/2014 1.0 222 0.8
0.8 335 05/03/2014 0.2 209 0.3
0.4 23/03/2015 0.7
0.1 508 29/10/2014 0.2 388
0.4 420 19/11/2014 0.9 184
0.2 286 03/12/2104 0.5 230
0.01 364 10/12/2014 0.4 274
0.05 344 11/02/2015 0.15 239
0.05 264 11/02/2015 0.9 205
0.05 305 01/04/2015 0.4 333
0.05 414 20/05/2015 0.15 379
0.01 03/06/2015 0.1
VA Sart CMT Start Date IVI-1 VA 1 year CMT 1 year VA 2 year
   cuity - Vision  Macular Thickness VA Year 1 CMT VA Year 2
Start 53 Eyes Start - 48 53 Year 1 - 48 24
      0.01 or 6/600  n Micrometers (um)
         ter the vision
CMT 2 year Date IVI-2 Date IVI-3
 (weeks since previous injection)4 4
4 4
4 5


















































CMT 2 year Date IVI-2 Date IVI-3
CMT
Year 2 - 24 
Date IVI-4 Date IVI-5 Date IVI-6 Date IVI-7 Date IVI-8 Date IVI-9
4 4 4 4 4 5
4 5 9 4 4 4
6 22 7
4
16 4 4 6 6 6
4 4 4 4 4 6
4 6 8 8 8 10
4 5 6 8 8 10
8 4 6 8 8 8
4 5 6 6 8 4
4 5 5 7 6 12
4 5 7 13 5 6
4 4 6 8
4 4 6 8 10 6
10 7 12 4 4 8
4 4 6 8 4 4
5 4 4 6 8 10
4 4 4 4 4 4
4 26
4 4 4 6 6 4
8 4 8 4 4 4
4 14 4
4 4 4 6 8 8
3 6 6 8 9 9
4 6 6 8 10 4
4 4 5 6 6 8
4 4 4 4 9 5
4 6 8 10 4 6
4 6 5 7 8 5
4 4 5 6 8 12
6 4 4 4 4 4
4 4 4 6 4 6
6 8 10 12 12 14
6 8 10 12 14
10 4 4 4 4 4
6 4 4 4 4 4
4 4 4 4 4 7
4 5 6 8 10 10
4 4 5 7 9 4
4 4 4 4 4 4
4 4 4 5 4 5
6 7 8 10 12 12
6 8 9 6 7 8
6 8 8 10
4 4 4 4 4 4
6 8 12 8 10
4 6 4 6 4 4
5 6 6 4 4 4
4 4 6 8 6 6
4 5 6 7 7
4 4 4 4 5 4
4 5 6 6 6 5
4 4 4 4 8 6
Date IVI-4 Date IVI-5 Date IVI-6 Date IVI-7 Date IVI-8 Date IVI-9
Date IVI-10 Date IVI-11 Date IVI-12 Date IVI-13 Date IVI-14 Date IVI-15
4 4 4
4 4 4
4 6 7 8 8 4
6 8 6 6 6 6
10 10 12 14
4
4
8 9 11 13 12
5 7 7 9 4 6
10 4 4 4 5 4
4 8 10 10 11
5 4 6
4 4 4
8 9 12 14 4
12 12
6 8 4 6 4 6
10 4 6 8 4 6
4 4 4
6 8 8 12 6 8
6
5 4 4 4 4 4
6 4 4
16 16
4 5 6 8 8 10
5 4 12 4 6 6
4 6 6 8 10 11
12 14
6 8 4 4 4 4
4 4 6 5 5 4
4 5 4 4 5 6
12 12
10 12 12 12







Date IVI-10 Date IVI-11 Date IVI-12 Date IVI-13 Date IVI-14 Date IVI-15
Date IVI-16 Date IVI-17 Date IVI-18 Date IVI-19 Date IVI-20
4 6 4 6
13 8 4 4
6 8 4
9 4 6
8 4 4 4 4
4 6 8 4




6 6 7 7
4 5 6 6 5
7 7 9
Date IVI-16 Date IVI-17 Date IVI-18 Date IVI-19 Date IVI-20






















































Date IVI-21 Date IVI-22 Total number Injection Year 1
Total = 511
Mean = 9.64 

























Total number Injections Year 2
Total = 144 
Mean = 6 
